Poster session I Friday June 16

Education sessions | Lunch debates | Opening Ceremony | ESH-EHA Joint Symposium | Poster Session I


Poster presentation during Poster-walks from 17.45 - 19.00 hours Poster area (behind Exhibition)

POSTER SESSION I

17.45 - 19.00 hours, Poster area (behind Exhibition)

IRON DISEASES

0001 5 YEARS OF COMBINED CHELATION THERAPY: A RADICAL CHANGE IN BETA-THALASSAEMIA MAJOR PATIENT CONDITION
K.F. Farmaki (General Hospital of Corinth, Corinth, Greece
 
0002 PEARSON SYNDROME IN AN INFANT HETEROZYGOUS FOR C282Y ALLELE OF HFE GENE
E. Roilides, K. Kefala-Agoropoulou, E. Roilides, E. Karatza, A. Lazaridou, E. Farmaki, P. Augoustides-Savvopoulou, C. Tsantali, J. Tsiouris (Aristotle University, Thessaloniki, Greece
 
0003 CHELATION THERAPY WITH DEFERASIROX VERSUS DEFEROXAMINE IN TRANSFUSION-DEPENDENT SICKLE-CELL DISEASE: A COST-EFFECTIVENESS ANALYSIS FROM THE US PERSPECTIVE
E Delea, O. Sofrygin, J.F. Baladi, S.K. Thomas, T.D. Coates (Policy Analysis Inc. (PAI), Brookline, Ma, USA
 
0004 MANNOSE BINDING LECTIN LEVELS IN THALASSEMIC PATIENTS WITH HEPATITIS C TREATED WITH PEGINTERFERON ALPHA-2?
I. Papassotiriou, H. Berdoussi, H. Hantzi, A. Kattamis, C. Kattamis, V. Ladis (Aghia Sophia Children's Hospital, Athens, Greece
 
0005 EFFECTIVENESS AND SAFETY OF LONG-TERM COMBINATION IRON CHELATION THERAPY WITH DESFERRIOXAMINE (DFO) & DEFERIPRONE (DFP) IN MULTITRANSFUSED PATIENTS WITH THALASSAEMIA
S. Fragatos-Pateraki, C. Polotis, K. Vendiadi (3rd Regional Blood Transfusion Centre, Athens, Greece
 
0006 CHELATION EFFICACY OF DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH THALASSEMIA MAJOR
D. Lee, F. Tricta, Y.C. Tsang, M. Spino (ApoPharma Inc., Toronto, Canada
 
0007 THE ROLE OF RETICULOCYTE HEMOGLOBIN CONTENT (CHR) AS IRON STATUS MARKER IN HAEMODIALYSIS PATIENTS
J.M. Kim, C.H. Ihm, H.J. Kim (Eulji University Hospital, Daejeon, South-Korea
 
0008 SENSITIVITY ANALYSIS ON THE COST-EFFECTIVENESS OF CHELATION THERAPY WITH DEFERASIROX OR DEFEROXAMINE IN TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS BASED ON EUROPEAN COSTS
E. Delea, O. Sofrygin, J.F. Baladi, S.K. Thomas, P.D. Phatak, T.D. Coates (Policy Analysis Inc. (PAI), Brookline, Ma, USA)
 
0009 BURDEN OF IRON CHELATION THERAPY SIGNIFICANTLY IMPACTS ADHERENCE TO TREATMENT IN PATIENTS WITH IRON OVERLOAD
D. Rofail, M. Viala, E. Trudeau, J.F. Baladi (Mapi Values Ltd, Bollington, United Kingdom)
 
0010 EFFECTS OF SILYMARIN ON TELOMERASE ACTIVITY AND PROLIFERATION OF PERIPHERAL BLOOD T-LYMPHOCYTES IN ß-THALASSEMIA MAJOR PATIENTS?
B. Bagherpour, B. Moayedi, M. Gharagozlu, M. Tahanian, H. Hourfar,
L. Khodadadi, H. Mirmohammadsadeghi (School of Medicine, Isfahan,
Iran)
 
0011 HEPCIDIN MUTATION IN A BETA-THALASSEMIA MAJOR (TM) PATIENT WITH PERSISTENT SEVERE IRON OVERLOAD DESPITE CHELATION THERAPY
L. Duca, P. Delbini, I. Nava, A. Meo, M. La Rosa, L. Zanghì, M.D. Cappellini (University of Milan-Policlinico Hospital, Milan, Italy)
 

ANEMIA / RED BLOOD CELLS I

0012 EARLY MARKERS OF RENAL DYSFUNCTION IN PATIENTS WITH SICKLE CELL / BETA-THALASSEMIA
E. Voskaridou, E. Terpos, S. Michail, E. Hantzi, A. Anagnostopoulos, A. Margeli, D. Simirloglou, D. Loukopoulos, I. Papassotiriou (Thalassemia Center, Laikon Gen. Hospital, Athens, Greece)
 
0013A PHASE I, SINGLE AND FRACTIONATED, ASCENDING DOSE STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF AN ERYTHROPOIETIC MIMETIC ANTIBODY FUSION PROTEIN, CNTO528, IN HEALTHY MALE SUBJECTS
K.L. Franson, J. Burggraaf, E.A. Bouman-Thio, M.B.A. Van Doorn, A.F. Cohen, B.E. Miller, H. Jang, S.J. Marciniak, E.P.S. Van de Ketterij, B. Frederick, Q. Jiao, J. Getsy, E.H. Bald, A. Schantz, J.A. Ford
(CHDR, Leiden, The Netherlands)
 
0014CORRECTION OF ANEMIA OF THE POST-OPERATIVE PERIOD AFTER ORTHOPEDIC SURGERY BY ORAL VERSUS INTRAVENOUS IRON VERSUS INTRAVENOUS IRON + EPO: A PROSPECTIVE
RANDOMIZED TRIAL
P. Beris, F. Verholen, M. Sadowski, M. Noger, P. Hoffmeyer (Geneva University Hospitals, Geneva, Switzerland)
 
0015 A NON-INVASIVE EVALUATION OF HEMATOCRIT WITHA NEW OPTICAL SENSOR
A. Berrebi, O. Amir, A. Weinstein, O. Herzenstein, D. Dvir, E. Monashkin, E. Gabis, P. Holland (Kaplan Medical Center, Rehovot, Israel)
 
0016BODY IRON BALANCE AND IRON EXCRETION: INTAKE RATIO, ACCORDING TO TRANSFUSIONAL REQUIREMENTS, DURING TREATMENT WITH THE ONCE-DAILY ORAL IRON CHELATOR DEFERASIROX (ICL670)
M.D. Cappellini, C. Vermylen, I. Gathmann, J.M. Ford (Universita di Milano, Milan, Italy)
 
0017 EPOETIN BETA 30 000 IU ONCE WEEKLY IS EFFECTIVE AND WELL TOLERATED IN ANEMIC PATIENTS WITH SOLID OR NON-MYELOID HEMATOLOGICAL MALIGNANCIES RECEIVING CHEMOTHERAPY: RESULTS FROM THE NAUTICA STUDY
D. Spaeth, G. Salles, T. Facon, R. Garidi, I. Vaida, P. Fiorentini, L. Bergougnoux (Polyclinique de Gentilly, Nancy, France)
 
0018 PATIENT CONTROLLED ANALGESIA VERSUS CONTINUOUS INFUSION OF MORPHINE DURING VASO-OCCLUSIVE CRISIS IN SICKLE CELL DISEASE: A RANDOMIZED CONTROLLED TRIAL
E.J. van Beers, P.T. Nieuwkerk, C.F.J. van Tuijn, P.W. Friederich, J.H. Franken, B.J. Biemond (Academic Medical Centre, Amsterdam, The Netherlands)
 
0019 EX VIVO ANALYSIS OF PKLR MUTATIONS THAT AFFECT CORRECT PROCESSING OF PKLR MRNA CAUSING PYRUVATE KINASE DEFICIENCY
R. van Wijk, A. van Wesel, G. Rijksen, W.W. van Solinge (University Medical Center Utrecht, Utrecht, The Netherlands)
 
0020 ASSESSMENT OF COGNITIVE EFFECTS OF ONCE-WEEKLY EPOETIN ALFA IN ANEMIC PATIENTS WITH HEMATOLOGIC MALIGNANCIES RECEIVING CHEMOTHERAPY: RESULTS OF THE EPOLYM TRIAL
H. Tesch, A.M. Liberati, N. Ifrah, - Epolym Investigators (Onkologische Gemeinschaftspraxis, Frankfurt, Germany)
 
0021 NON-TRANSFERRIN-BOUND IRON AND OXIDATIVE STRESS ARE RELATED TO THE DEGREE OF ERYTHROPOIESIS IN PATIENTS WITH THALASSAEMIA INTERMEDIA
I. Papassotiriou, C. Lazaropoulou, E. Kanavakis, V. Ladis, G. Paleologos, A. Stamoulakatou, C. Kattamis, A. Kattamis (Aghia Sophia Children's Hospital, Athens, Greece)
 
0022 DEFERASIROX (EXJADE(R), ICL670), THE NOVEL, ONCE-DAILY ORAL IRON CHELATOR, IS WELL TOLERATED AND EFFECTIVE IN TREATING TRANSFUSIONAL IRON OVERLOAD IN PATIENTS WITH A RANGE OF RARE ANAEMIAS
C. Rose, N. Gattermann, E. Glimm, B. Rabault (Hôpital Saint Vincent de Paul, Lille, France)
 
0023 GLYCOCALYX PERTURBATION IN PATIENTS WITH SICKLE CELL DISEASE: IMPLICATIONS FOR VASCULAR VULNERABILITY
E.J. van Beers, M. Nieuwdorp, H. Vink, L.M. Evers, B.J. Biemond (Academic Medical Centre, Amsterdam, The Netherlands)
 
0024 THE DIFFERENTIAL DIAGNOSIS OF INHERITED SIDEROBLASTIC ANAEMIA
A. May, B.C. Kerr, S.D. Whatley, J. Woolf (Cardiff University School of Medicine, Cardiff, United Kingdom)
 
0025 INTRAVENOUS ZOLEDRONIC ACID TREATMENT IN THALASSAEMIA-INDUCED OSTEOPOROSIS: RESULTS OF A PHASE II CLINICAL TRIAL
A . Taher, Z. Otrock, S. Azar, W. Shamseddeen, D. Habr, A. Inati, S. Koussa, R. Mahfouz (American University of Beirut Medical Ct, Beirut, Lebanon)
 
0026 THE DISTINCTION BETWEEN HAEMOLYSIS DUE TO HEREDITARY SPHEROCYTOSIS AND THAT DUE TO A CATION PERMEABILITY DISORDER OF THE RED CELL MEMBRANE IN A REGULAR HAEMATOLOGY LABORATORY
J.S. Goede, R. Rüegg, G.W. Stewart, P. Harrison, H.C. Robinson, T. Latshang, J. Fehr, J.C. Ellory, H.U. Lutz (City Hospital Triemli, Zurich, Switzerland)
 
0027 RITUXIMAB AND FLUDARABINE COMBINATION THERAPY FOR CHRONIC COLD AGGLUTININ DISEASE
S. Berentsen, G.E. Tjonnfjord (Haugesund Hospital, Haugesund, Norway)
 
0028 IN VIVO OXIDATIVE ERYTHROCYTE MEMBRANE PROTEIN DAMAGE IN HEREDITARY SPHEROCYTOSIS
I. Margetis, M. Antonelou, F. Karababa, A. Loutradi, L. Margaritis, I. Papassideri (University of Athens, Athens, Greece)
 
0029 DARBEPOETIN ALFA ADMINISTERED EVERY 3 WEEKS WITH OR WITHOUT PARENTERAL IRON IN ANAEMIC PATIENTS WITH NONMYELOID MALIGNANCIES RECEIVING CHEMOTHERAPY: INTERIM RESULTS FROM A RANDOMISED OPEN-LABEL STUDY
A. Vandebroek, S. Altintas, B. Gaede, K. Smith, B. Yao, M. Schupp (Ziekenhuisnetwerk Antwerpen, Antwerpen, Belgium)
 
0030 CHARACTERISATION OF INDIVIDUAL NADH-CYTOCHROME B5 REDUCTASE VARIANTS USING A HETEROLOGOUS EXPRESSION SYSTEM
M.J. Percy, L.J. Crowley, C.A. Davis, J. Boudreaux, D.M. Layton, M.F. McMullin, T.R.J. Lappin, M.J. Barber (Belfast City Hosptial, Belfast, United Kingdom)
 
0031 DEFERASIROX (ICL670) PROVIDES 24-HOUR PROTECTION FROM LABILE PLASMA IRON (LPI), IN IRON OVERLOADED ß-THALASSAEMIA PATIENTS PREVIOUSLY CHELATED WITH MONO- OR COMBINATION THERAPY
S. Daar, A. Taher, A. Pathare, U. Krahn, C. Ressayre-Djaffer, H. Nick, D. Hadler (Sultan Qaboos University, Muscat, Oman)
 
0032 RESIDUAL IRON LOAD ESTIMATED BY T2* MAGNETIC RESONANCE IN EXTHALASSEMIC PATIENTS LONG-TIME AFTER BONE-MARROW TRANSPLANTATION
V. Ladis, S. Mavrogeni, E. Gotsis, H. Berdousi, F. Petropoulos, A. Kattamis ("Agia Sofia" Children's Hospital, Athens, Greece)
 

A DRUG RESISTANCE & DRUG PHARMACOLOGY

 
0033 GENETIC AND LEUKAEMIA-SPECIFIC FACTORS ASSOCIATED WITH P-GLYCOPROTEIN EXPRESSION AND FUNCTION IN AML BLASTS
C. Seedhouse, M. Grundy, P. White, Y. Li, J. Fisher, D. Yakunina, N. Russell, A. Burnett, M. Pallis (Nottingham City Hospital, Nottingham, United Kingdom)
 
0034 FCGRIIIA 158 V/V GENOTYPE IS ASSOCIATED WITH INFERIOR RESPONSE TO RITUXIMAB AND CHOP IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
Z. Mitrovic, I. Aurer, I. Radman, R. Ajdukovic, J. Sertic, B. Labar (University Hospital Center Zagreb, Zagreb, Croatia)
 
0035 DEFINED BONE MARROW NICHE COMPONENTS MEDIATE THE IN VITRO RESISTANCE OF AML SAMPLES TO THE TYROSINE KINASE INHIBITOR AG1296 AS WELL AS TO CYTOSINE ARABINOSIDE
M. Pallis, U. Mony, D. Cardosa, C. Seedhouse, N. Russel (Nottingham City Hospital, Nottingham, United Kingdom)
 
0036 OVERCOMING CHEMORESISTANCE IN HUMAN CHRONIC MYELOID LEUKEMIA K562 CELLS BY SIRNA INHIBITION OF SHINGOSINE KINASE-1
Y.B. Baran, J.B. Bielawski, C.E.S. Senkal, B.O. Ogretmen, U.G. Gunduz (Middle East Technical University, Ankara, Turkey)
 
0037 DEMONSTRATION OF SYNERGISTIC GROWTH-INHIBITORY EFFECTS OF DASATINIB AND CLADRIBINE IN NEOPLASTIC HUMAN MAST CELLS
K.V. Gleixner, M. Mayerhofer, K. Sonneck, A. Gruze, P. Samorapoompichit, F.Y. Lee, W.F. Pickl, C. Sillaber, P. Valent (Institute of internal medecine, Vienna, Austria)
 
0038 SENSITIZING LEUKEMIC CELLS TO GLUCOCORTICOSTEROIDS BY INHIBITING NFKB ACTIVATION
J. Vink, J. Cloos, R. Oerlemans, C.H. van Zantwijk, J.W. van der Heijden, G. Jansen, G.J.L. Kaspers (VU University Medical Center, Amsterdam, The Netherlands)
 
0039 RAPAMYCIN OVERCOMES DEXAMETHASONE RESISTANCE OF MALIGNANT PLASMA CELLS
F. Bakker, A. Ott, K. Richter, T. Ahrens, R. Burger, A. Guenther, M. Gramatzki (2nd Medical Department, Kiel, Germany)
 
0040 MULTIDRUG RESISTANCE MECHANISMS IN HUMAN CHRONIC MYELOID LEUKEMIA CELLS
Y.B. Baran, A. U. URAL, B.O. Ogretmen, U.G. Gunduz (Middle east Technical University, Ankara, Turkey)
 
0041 IDENTIFICATION AND CHARACTERIZATION OF A HOMO-DIMER OF ABCG2 IN MATURE HUMAN ERYTHROCYTES
M.L. Leimane, E.G. Georges (McGill University, Montreal, Canada)
 
0042 FUNCTIONAL AND GENOME-WIDE ANALYSIS OF ACQUIRED RESISTANCE TO TRAIL/APO2L MEDIATED APOPTOSIS OF HL60 LEUKEMIA CELLS
P. Klener, R. Kralovics, P. Prochazka, A. Vicha, T. Eckschlager, E. Necas, L. Andera, J. Zivny (Charles University, 1st Medical Faculty, Praha, Czech Republic)
 
0043 THE ADMINISTRATION OF REPEATED DOSES OF CYCLOPHOSPHAMIDE, INDUCES CYTOCHROME P450 IN RAT
P. Afsharian, Y. Terelius, Z. Hassan, S. Lundgren, M. Hassan (Karolinska Institutet, Stockholm, Sweden)
 
0044 OPTIMIZATION OF THERAPY FOR THIOPURINE S-METHYLTRANSFERASE DEFICIENT CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
B. Petrucev, L. Dokmanovic, N. Tosic, D. Janic, N. Jovanovic, S. Pavlovic (IMGGE, Belgrade, Serbia and Montenegro)
 
0045 IMATINIB AND HUMAN ORGANIC CATION TRANSPORTER 1 (HOCT1): CHARACTERISATION OF TRANSPORT IN STABLY TRANSFECTED MYELOID CELLS
A. Giannoudis, L. Wang, R.E. Clark, M. Pirmohamed (University of Liverpool, Liverpool, United Kingdom)
 

MOLECULAR DIAGNOSTICS

0046 PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE (MRD) MONITORING ON RELAPSE-FREE SURVIVAL IN CBFB-MYH11 ACUTE MYELOID LEUKEMIA (AML)
A. Corbacioglu, C. Scholl, K. Eiwen, L. Bullinger, S. Fröhling, H. Döhner, R.F. Schlenk, K. Döhner (University Hospital of Ulm, Ulm, Germany)
 
0047 CHARACTERIZATION OF THREE CASES OF ANEMIA/ MENTAL RETARDATION SYNDROMES (ATR-16) IN THE NETHERLANDS, USING MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION (MLPA)
C.L. Harteveld, M. Kriek, E.K. Bijlsma, Z. Erjavec, A. Voskamp, D. Balak, P.C. Giordano (Leiden University Medical Center, Leiden, The Netherlands)
 
0048 INDIVIDUAL PATIENT DATA ANALYSIS IN YOUNGER ADULTS WITH NORMAL KARYOTYPE AML: DIFFERENTIAL EFFECTS OF MOLECULAR MARKERS ON CLINICAL OUTCOME. RESULTS OF THE AML STUDY GROUP (AMLSG)
K. Döhner, A. Corbacioglu, J. Krauter, L. Bullinger, D. Späth, I. Schäfer, S. Fröhling, A. Ganser, H. Döhner, R.F. Schlenk (University of Ulm, Ulm, Germany)
 
0049 DEVELOPMENT OF AN INTEGRATED ASSAY FOR QUANTITATIVE REAL TIME DETECTION OF BCR-ABL RNA FROM PERIPHERAL BLOOD
E.S. Winn-Deen, B. Helton, R. Van Atta, W. Wong, J.P. Peralta, J.J. Wang, J. Radich, L. Beppu, G.J. Tsongalis, D.R. Belloni, D. Chan, J.R. Eschelman, C.D. Gocke, Z. Jobbagy (Cepheid, Sunnyvale, Ca, USA)
 
0050 HARMONIZATION OF BCR-ABL TRANSCRIPT QUANTIFICATION USING AN UNIFORM CONTROL PLASMID IN 37 INTERNATIONAL LABORATORIES
M.C. Müller, P. Erben, G. Saglio, E. Gottardi, T. Schenk, T. Ernst, S. Lauber, J. Kruth, R. Hehlmann, A. Hochhaus (Universitätsklinikum Mannheim, Mannheim, Germany)
 
0051 THE IDENTIFICATION OF JAK2V617F IN PATIENTS WITH POLYCYTHAEMIA IS HIGHLY CORRELATED WITH CONVENTIONAL CRITERIA FOR DIAGNOSIS OF POLYCYTHAEMIA VERA
P. Ganly (Christchurch School of Medicine, Christchurch, New Zealand)
 
0052 IDENTIFICATION OF A COMMONLY USED CDR3 REGION OF LGLS TCR ALPHABETA+/CD4+ VBETA 13.1 PATIENTS
P. Garrido, A. Orfao, J. Canton, J. Almeida, M. Lima, P. Barcena, M.A. Lopez- Nevot, F. Garrido, F. Ruiz-Cabello (Virgen de las Nieves Hospital, Granada, Spain)
 
0053 MDR1, MRP AND LRP EXPRESSION IN PATIENTS WITH UNTREATED ACUTE LEUKEMIA: CORRELATION WITH TC-99M MIBI BONE MARROW SCINTIGRAPHY
I. Ak, G. Demirel, Z. Gulbas (Eskisehir Osmangazi University, Eskisehir, Turkey)
 
0054 REAL-TIME RT-PCR ASSAY USING THE TAQMAN PROBES WITH LNA (LOCKED NUCLEIC ACID) MODIFICATION TO DETERMINE JAK2 GENE V617F MUTATIONS IN MYELOPROLIFERATIVE DISEASES (MPD)
J. Marková, J. Schwarz (Institute of Hematology and Blood Transfusion, Prague, Czech Republic)
 
0055 HIGH FREQUENCY OF AML1 MUTATIONS IN BOTH DE NOVO MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA BUT WITH DIFFERENT MUTATION PATTERNS
L.Y. Shih, D.C. Liang, C.F. Huang, J.H. Wu, Y.S. Shih, P.N. Wang, M.C. Kuo, P. Dunn, T.L. Lin, T.C. Tang, H. Chang (Chang Gung Memorial Hospital, Taipei, Taiwan)
 
0056 NPM1 AND FLT3 MUTATIONS, DUPLICATIONS OF MLL AND EXPRESSION OF GENES WT1, EVI AND BAALC AS PROGNOSTIC FACTORS IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA
S. Ballester, E. Barragán, J. Cervera, P. Bolufer, E. Afan de Ribera, P. Fernandez, R. Andreu, R. Collado, G. MARTÍN, P. Montesinos, J.C. Pajuello, M. Collado, M. Maiques, C. Martin, M.A. Sanz (Hospital La Fe, Valencia, Spain)
 
0057 ACCURATE V617F JANUS KINASE (JAK) 2 MUTATION GENOTYPING COMBINING ARMS PCR AND CAPILLARY ELECTROPHORESIS
F. C. Lambert, A. Schioppa, S. Castermans, M. Lopezy Cadenas, A. Chariot, V. Bours (University of Liège, Liège, Belgium)
 
0058 COOPERATING MUTATIONS OF RECEPTOR TYROSINE KINASES AND RAS SIGNALING PATHWAY IN CHILDHOOD CORE-BINDING FACTOR AML WITH EMPHASIS ON C-KIT MUTATION AND A COMPARATIVE STUDY BETWEEN DIAGNOSIS AND RELAPSE
D.C. Liang, L.Y. Shih, C.F. Huang, Y.T. Chang, C.L. Lai, I.J. Hung, C.P. Yang, T.H. Jaing, H.C. Liu, L.Y. Wang, T.C. Yeh (Mackay Memorial Hospital, Taipei, Taiwan)
 
0059 SENSITIVE DETECTION OF C-KIT POINT MUTATIONS IN PATIENTS WITH MASTOCYTOSIS BY D-HPLC
P. Erben, M.C. Müller, T. Schenk, G. Metzgeroth, S. Lauber, J. Kruth, T. Ernst, P. Paschka, R. Hehlmann, A. Reiter, A. Hochhaus (III. Med. Klinik Mannheim University of Heidelberg, Mannheim, Germany)
 
0060 MUTATIONAL SCREENING IN A POPULATION OF HAEMOPHILIA A SUBJECTS FOLLOWED AT THE HAEMOPHILIA CENTRE IN CENTRO HOSPITALAR DE COIMBRA
C. Silva Pinto, T. Fidalgo, D. Marques, E. Gonçalves, P. Martinho, R. Salvado, N. Martins, M.L. Ribeiro (Centro Hospitalar de Coimbra, Coimbra, Portugal)
 
0061 MOLECULAR CLINICAL CORRELATION OF G6PD DEFICIENCY IN WESTERN SAUDI ARABIA
S.K. Al Jaouni (King Abdulaziz University, Jeddah, Saudi Arabia)
 
0062 PREVALENCE OF NMP1 MUTATION IN AML AND MDS
C.E. Lopez Jorge, P. Martin, J. Lopez Brito, M.T. Gomez Casares, J.D Gonzalez San Miguel, A. Lemes, T. Ramirez, G. Santana, R. Mataix, S. De La Iglesia, H. Luzardo, T. Molero (Hospital Universitario Doctor Negrin, Las Palmas De Gran Canaria, Spain)
 
0063 THE COMPARISON OF THE RESULTS OF MOLECULAR MONITORING OF IMATINIB THERAPY IN CML BCR-ABL POSITIVE PATIENTS USING QPCR AND TWO CONTROL REFERENCE GENES
K. Lewandowski, M. Baranska, M. Lewandowska, M. Iwola, D. Drozdowska, J. Rupa, M. Komarnicki (University of Medical Sciences, Poznan, Poland)
 
0064 IMPROVED EFFICIENCY IN MOLECULAR DIAGNOSIS OF T(14;18)(Q32;Q21) AND T(11;14)(Q13;Q32) USING MULTIPLEXAND LONG DISTANCE INVERSE-PCR
L. Vieira, A. Martinho, E. Silva, C. Silva, E. Júnior, P. Jordan (Instituto Nacional de Saúde, Lisboa, Portugal)
 

MOLECULAR TARGETING AND GENE THERAPY

 
0065 THE EFFECT OF HISTONE DEACETYLASE INHIBITORS ON B-CELL DIFFERENTIATION IS NOT UNIQUE FOR TEL-AML1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAS
M.L. Den Boer, W.A.G. Stams, H.B. Beverloo, E.R. Van Wering, G.E. Janka-Schaub, R. Pieters (Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands)
 
0066 IMATINIB MESYLATE CAN INDUCE MOLECULAR COMPLETE REMISSION IN IDIOPATHIC HYPEREOSINOPHILIC SYNDROME (HES). A PHASE II MULTICENTRIC ITALIAN CLINICAL TRIAL
M. Rondoni, D. Cilloni, E. Ottaviani, PP. Piccaluga, M. Malagola, F. Messa, E. Gottardi, S. Soverini, S. Merante, G. Alimena, F. Pane, S. Paolini, F. Rancati, G. Saglio, M. Baccarani, G. Martinelli (University of Bologna, Bologna, Italy)
 
0067 SIRNA VERSUS LOCKED NUCLEIC ACID RNA ANTAGONISTS: STAY SINGLE!
P. Kearney, M. Westergaard, E.M. Staarup, H.F. Hansen, T. Koch, J.B. Hansen, H. Oerum (Santaris Pharma, Copenhagen, Denmark)
 
0068 DUAL SRC/ABL INHIBITOR SKI-606 BINDING MODE IN BCR-ABL KINASE HYPOTHESIZED ON THE BASIS OF MOLECULAR DOCKING STUDIES
S. Soverini, G. Tasco, T. Grafone, S. Colarossi, A. Gnani, G. Rosti, F. Castagnetti, F. Palandri, M. Rondoni, A. Poerio, I. Iacobucci, M. Amabile, M. Baccarani, R. Casadio, G. Martinelli (University of Bologna, Bologna, Italy)
 
0069 EFFECTIVE INHIBITION OF BCR/ABL KINASE WITH TETRAMERIZATION DOMAIN DERIVED PEPTIDES MAPES TO COILED-COIL HELIX-ALPHA-2
T. Beissert, V. Kaburova, A. Mian, O.G. Ottmann, D. Hoelzer, M. Ruthardt (University Clinic Frankfurt, Frankfurt, Germany)
 
0070 SINGLE-AGENT SU11657, A NOVEL FLT3 INHIBITOR, SHOWS BIOLOGIC ACTIVITY IN ACUTE MYELOID LEUKEMIA CELLS IN VITRO
T. Grafone, E. Ottaviani, M. Palmisano, M. Mancini, N. Testoni, M. Amabile, C. Terragna, A. Poerio, M. Renzulli, S. Soverini, S. Colarossi, I. Iacobucci, M. Baccarani, G. Martinelli (Inst. of Hematology "Seràgnoli", Bologna, Italy)
 
0071 POTENTIAL THERAPEUTIC APPROACH OF RECOMBINANT TRAIL IN CML IN BLAST CRISIS
A.C. Gonçalves, A. Oliveira, D. Moreira, C. Costa, J.E. Lopes, C.J. Andrade, T. Silva, V. Alves, M. Dourado, A.B. Sarmento-Ribeiro (Faculty of Medicine of Coimbra, Coimbra, Portugal)
 
0072 RCE1 DEFICIENCY ACCELERATES THE DEVELOPMENT OF A K-RAS INDUCED MYELOPROLIFERATIVE DISEASE
M. Liu, A.M. Wahlstrom, K.M.E. Andersson, C. Karlsson, A.K. Sjögren, B. Cutts, S.G. Young, M. Bergo (Sahlgrenska University Hospital, Gothenburg, Sweden)
 
0073 OPTIMIZING T CELL RECEPTOR GENE TRANSFER TO VIRUS-SPECIFIC T CELLS FOR CLINICAL APPLICATION
M. Griffioen, H.M. van Egmond, M.A.W.G. van der Hoorn, R.S. Hagedoorn, M. Kester, R. Willemze, J.H.F. Falkenburg, M.H.M. Heemskerk (Leiden University Medical Center, Leiden, The Netherlands)
 
0074 DUAL SPECIFIC T CELLS CHANGE THEIR T CELL RECEPTOR (TCR) CELL SURFACE DISTRIBUTION UPON TCR TRIGGERING
M.M. van Loenen, R.S. Hagedoorn, M Hoogeboom, M.G.D. Kester, R. Willemze, J.H.F. Falkenburg, M.H.M. Heemskerk (Leiden University Medical Center, Leiden, The Netherlands)
 
0075 RELEVANCE OF MEK/ERK ACTIVATION IN THE MAINTENANCE OF THE PML/RAR-ALPHA INTEGRITY IN ACUTE PROMYELOCYTIC LEUKEMIA
N. Barbarroja Puerto, E. Siendones Castillo, P. Buendia Bello, L.A. Torres Sanchez, F. Velasco Gimena, A. Torres Gomez, Ch. Lopez Pedrera (Hospital Universitario Reina Sofia, Cordoba, Spain)
 
0076 TRANSCRIPTIONAL PROFILING OF PROTEASOME INHIBITOR-MEDIATED ANTI-TUMOR ACTIVITY IN EPSTEIN-BARR VIRUS-INFECTED NASAL NK LYMPHOMA CELLS
J. Ohyashiki, Y. Zhang, R. Hamamura, N. Shimizu, K. Ohyashiki (Tokyo Medical University, Tokyo, Japan)
 
0077 SIRNA-MEDIATED MLL-AF4 KNOCKDOWN AFFECTS TERT EXPRESSION
J.G. Greil, M. Thomas, P. Gessner, O. Heidenreich (University of Heidelberg, Heidelberg, Germany)
 
0078 PRENYLATION INHIBITORS MODULATE IL-6 AND IGF-1 DEPENDENT SIGNALING IN MULTIPLE MYELOMA CELLS
T. Sebil, D. Peest, A. Ganser, C.W.M. Reuter, M.A. Morgan (Hannover Medical School, Hannover, Germany)
 
0079 EFFECTS OF BORTEZOMIB IN APOPTOSIS IN B-CLL CELLS INDEPENDENTLY OF PRIOR THERAPY - CHARACTERIZATION OF BIOCHEMICAL MECHANISMS ASSOCIATED WITH THE RESPONSE
A.B. Sarmento-Ribeiro, M. Dourado, A.C. Gonçalves, E. Cortesão, C. Geraldes, L. Rito, I. Sousa, R. Afonso, A. Paiva, A. Pereira, F. Guedes, C. Resende de Oliveira, A. Teixeira (Faculty of Medicine, Coimbra, Portugal)
 
0080 NO EVIDENCE FOR CONSTITUTIVELY ACTIVATED FLT3 IN JUVENILE MYELO-MONOCYTIC LEUKEMIA
A.C.H. de Vries, M.L. den Boer, M.M. van den Heuvel-Eibrink, R. Pieters, P. Schneider, R.W. Stam, E.R. van Wering, C.P. Kratz, C.M. Niemeyer, O.A. Haas (ErasmusMC-Sophia, Rotterdam, The Netherlands)
 
0081 MOLECULAR TARGETS OF THE PROTEASOME INHIBITOR, BORTEZOMIB, ON ADULT T-CELL LEUKEMIA CELLS
R. Hamamura, J. Ohyashiki, T. Takaku, S. Honda, K. Ohyahsiki (Tokyo Medical University, Tokyo, Japan)
 
0082 ANTISENSE THERAPY AGAINST MULTIDRUG RESISTANT GENE (MDR1) IN ACUTE MYELOBLASTIC LEUKEMIA CELL LINE
F. Nadali, A. Pourfathollah, K. Ali-moghaddam, A. Dizaji, A. Zomorodipour, E. Azizi, S. Rostsmi, A. Ghavamzadeh (School of Medicine, Isfahan, Iran)
 
0083 IDENTIFICATION OF HSP-32 = HEME OXYGENASE-1 (HO-1) AS A NOVEL KIT D816V-DEPENDENT TARGET IN NEOPLASTIC MAST CELLS IN SYSTEMIC MASTOCYTOSIS
R. Kondo, M. Mayerhofer, K.V. Gleixner, A. Vales, M.T. Krauth, K.J. Aichberger, S. Derdak, A. Gruze, W. Pickl, C. Sillaber, H. Maeda, P. Valent, K. Greish (Vienna Medical University, Vienna, Austria)
 

CHRONIC MYELOPROLIFERATIVE DISORDERS I

 
0084 EPHA3 TYROSINE KINASE RECEPTORS AS TARGETS IN CHRONIC MYELOPROLIFERATIVE DISEASES
A. Chiarenza, F. Messa, S. Carturan, R. Catalano, F. Arruga, I. Defilippi, V. Rosso, D. Di Giovanni, P. Nicoli, A. Morotti, E. Messa, A. Serra, E. Bracco, G. Saglio, D. Cilloni (University of Turin, Turin, Italy)
 
0085 IDENTIFICATION OF MCL-1 AS A NOVEL TARGET IN NEOPLASTIC HUMAN MAST CELLS: EVIDENCE FOR COOPERATIVE GROWTHINHIBITORY EFFECTS OF MCL-1 ANTISENSE OLIGONUCLEOTIDES, PKC412, AND AMN107
J. Aichberger, M. Mayerhofer, V. Gleixner, T. Krauth, A. Gruze, F. Pickl, V. Wacheck, E. Selzer, H. Agis, C. Sillaber, P. Valent (Medical University of Vienna, Vienna, Austria)
 
0086 ANAGRELIDE: STUDIES ON ITS MODE OF ACTION USING DIFFERENT MODEL SYSTEMS OF MEGAKARYOCYTE DIFFERENTIATION
J.D. Erusalimsky, A. Gutierrez del Arroyo, J. Hernandez, G. Wang, Y. Hong (University College London, London, United Kingdom)
 
0087 TISSUE-PLASMINOGEN ACTIVATOR (T-PA) AND PLASMINOGEN ACTIVATOR INHIBITOR (PAI-1) IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA
R. Cacciola (Institute of Hematology, Catania, Italy)
 
0088 PLATELET, LEUKOCYTE AND COAGULATION ACTIVATION PATTERNS IN MYELOFIBROSIS WITH MYELOID METAPLASIA
A. Alvarez-Larrán, E. Arellano-Rodrigo, J.C. Reverter, N. Villamor, D. Colomer, A. Domingo, R. Vallansot, F. Cervantes, E. Arellano-Rodrigo, J.C. Reverter, N. Villamor, D. Colomer, A. Domingo, R. Vallansot, F. Cervantes (Hospital Clínic, Barcelona, Spain)
 
0089 EPIGENETIC ALTERATIONS AND MUTATION OF JAK2 TYROSINE KINASE IN PATIENTS WITH BCR/ABL NEGATIVE MYELOPROLIFERATIVE DISORDERS
E.B. Jost, N. do Ò, E. Dahl, C. Maintz, P. Jousten, L. Habets, J.G. Herman, S. Wilop, R. Osieka, O. Galm (UK Aachen, Aachen, Germany)
 
0090 CLINICOPATHOLOGIC HETEROGENEITY OF CHRONIC HYPEREOSINOPHILIC SYNDROMES -LONG-TERM EXPERIENCE ON 32 PATIENTS
G. Helbig, B. Stella-Holowiecka, S. Grosicki, M.K. Krawczyk, G.B. Bober, A.B. Baranski, I.K. Kniewska, J.M. Mazurek, J.P. Pajak, A.B.C. Bartkowska-Chrobok, J.H. Holowiecki (Silesian Medical University, Katowice, Poland)
 
0091 APPLICATION OF PRV-1 MRNA EXPRESSION LEVEL AND JAK2- V617F MUTATION FOR DIFFERENTIAL DIAGNOSTICS BETWEEN POLYCYTHEMIA VERA AND SECONDARY ERYTHROCYTOSIS. INFLUENCE OF INTERFERON THERAPY ON PRV-1 EXPRESSION
V.V. Tutaeva, M.A. Sokolova, N.V. Tsvetaeva, E.A. Semenova, V.L. Ivanova, T.I. Kolosheinova, A.V. Misurin, N.D. Khoroshko (Hematology Research Centre RAMS, Moscow, Russian Federation)
 
0092 INFLUENCE OF LONG TERM HYDROXYUREA TREATMENT ON PRV-1 EXPRESSION LEVEL IN POLYCYTHEMIA VERA PATIENTS
V.V. Tutaeva, M.A. Sokolova, N.V. Tsvetaeva, E.A. Semenova, V.L. Ivanova, T.I. Kolosheinova, A.V. Misurin, N.D. Khoroshko (Hematology Research Centre RAMS, Moscow, Russian Federation)
 
0093 V617F JAK2 MUTATION IN CHILDREN WITH ESSENTIAL THROMBOCYTHEMIA (ET)
M.L. Randi, M.C. Putti, M. Scapin, E. Pacquola, F. Fabris (University of Padua, Padova, Italy)
 
0094 PREVIOUS HISTORY OF THROMBOTIC COMPLICATION IS THE MAIN RISK FACTOR THAT INCREASES THE INCIDENCE OF THROMBOTIC EVENTS IN ESSENTIAL THROMBOCYTHEMIA PATIENTS
F. Radaelli, M. Colombi, V.R. Zilioli, S. Bramanti, A. Iurlo, A. Zanella (Ospedale Maggiore Policlinico, Mangiagal, Milano, Italy)
 
0095 RATIONALE AND DESIGN OF A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE CORTICOSTEROID-SPARING EFFECTS OF ANTI-IL5 MONOCLONAL ANTIBODY (MEPOLIZUMAB) IN SUBJECTS WITH HYPEREOSINOPHILIC SYNDROME (HES)
X. Parkin, M. Rothenberg, F. Roufosse, A. Klion, J. Denburg, J. Murray, L. Rosenwasser, L. Schwartz, P. Weller, K. Leiferman, A. Haig, G. Gleich (GlaxoSmithKline, Middlesex, United Kingdom)
 
0096 FIP1L1-PDGFRA+ HYPEREOSINOPHILIA: HOW MANY DISEASES ?
F.C. Lambert, L. De Leval, C. Herens, A. Chariot, V. Bours (University of Liège, Liège, Belgium)
 
0097 VEGF SERUM LEVELS AND VEGF BONE MARROW IMMUNOHISTOCHEMICAL EXPRESSION IN CHRONIC MYELOPROLIFERATIVE DISORDERS
K. Panteli, M. Bai, N. Zagorianakou, L. Bourantas, E. Hatzimichael, K. Bourantas (University of Ioannina, Ioannina, Greece)
 
0098 ARRAY COMPARATIVE GENOMIC HYBRIDIZATION REVEALS AN ABSENCE OF RECURRENT GENOMIC COPY NUMBER CHANGES IN ESSENTIAL THROMBOCYTHEMIA
B. Espinet, E. Puigdecanet, L. Florensa, E. González, M. Salido, B. Bellosillo, M.E. Pérez-Vila, C. Pedro, L. Sumoy, C. Besses, S. Serrano, F. Solé (Hospital del Mar, Barcelona, Spain)
 
0099 THE INCIDENCE OF DEL20Q12 BY INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION (I-FISH) IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE DISORDERS
L. Pantelidou, I. Bazdiara, G. Trypsianis, D. Margaritis, G. Xanthopoulidis, A. Anastasiadis, M. Baka, V. Kaloutsi, G. Bourikas, C. Tsatalas (Democritus University of Thrace, Alexandroupolis, Greece)
 
0100 ABNORMAL EXPRESSION OF THE WAP FAMILY SLPI GENE IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE DISORDERS
E. Antonioli, A. Pancrazzi, P. Guglielmelli, C. Bogani, A. Bosi, A.M. Vannucchi (Az Ospedaliero-Univarsitaria Careggi, Florence, Italy)
 
0101 CONGENITAL ERYTHROCYTOSIS AND POLYCYTHEMIA VERA IN CHILDREN AND ADOLESCENTS - AN ONLINE DATABASE FOR REGISTRATION OF PATIENTS AND DATA COLLECTION
M.C. Bento, H. Cario, J. Vidan, A. Villegas, M.L. Ribeiro (Centro Hospitalar Coimbra, Coimbra, Portugal)
 
0102 ERYTHROCYTOSIS AND THROMBOCYTOSIS IN CHILDHOOD: THE EXPERIENCE OF A SINGLE CENTRE.
U. Ramenghi, P. Quarello, D. Renga, A. Doria, S. Martino, L. Foglia, L. Alba, S. Carturan, P. Sterpone, F. D'Arajo, L. Garbarini, L. Farinasso (University of Torino, Torino, Italy)
 
0103 PREDICTIVE VALUE OF ALTERATIONS OF COAGULATION AND THE JAK2 MUTATION ON THE RISK OF THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA
C.B. Burgaleta, D. de Miguel, M. Lopez Rubio, C.B. Besses, B.B. Bellosillo, T.P. Pascual, B. Paramio, J. García Suárez, H.B. Bañas, C.P. Perez Calvo (Hospital U. Principe de Asturias, Alcalá De Henares, Spain)
 

ACUTE MYELOID LEUKEMIA I

 
0104 MOLECULAR PROFILING USING ARRAY-CGH AND GENE EXPRESSION PROFILING REVEALS NEW CANDIDATE GENES IN AML WITH NORMAL KARYOTYPE
F.G. Rücker, L. Bullinger, H.A. Kestler, P. Lichter, K. Döhner, A.A. Quirino, H. Döhner (University of Ulm, Ulm, Germany)
 
0105 CO-EXPRESSION OF CD34, MDR1 AND BCRP INDICATES A CLINICALLY RESISTANT PHENOTYPE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OF OLDER AGE.
M.M. van den Heuvel-Eibrink, B. van der Holt, P.J.M. Vossebeld, A.K. Burnett, W.U. Knauf, P.P. Piccaluga, M.F. Fey, G.E.G. Verhoef, E. Vellenga, G.J. Ossenkoppele, B. Lowenberg, P. Sonneveld (Erasmus Medical Center-Sophia, Rotterdam, The Netherlands)
 
0106 REPLICATIVE SENESCENCE INDUCTION IN GOOD-RISK ACUTE MYELOID LEUKEMIA
J.M. Zijlmans, S.J.J. Swiggers, H.B. Beverloo, B. Löwenberg, (Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands)
 
0107 PROGNOSTIC IMPACT OF FLOW CYTOMETRICALLY DETERMINED MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
W. Kern, D. Voskova, C. Schoch, S. Schnittger, T. Haferlach (MLL Munich Leukemia Laboratory, Munich, Germany)
 
0108 PROGNOSTIC RELEVANCE OF FLT3-TKD MUTATIONS IN AML: THE COMBINATION MATTERS- AN ANALYSIS OF 3082 PATIENTS
S. Schnittger, U. Bacher, C. Schoch, W. Kern, T. Haferlach (MLL, Munich, Germany)
 
0109 EXPRESSION OF TUMOR-ASSOCIATED ANTIGENS IN ACUTE MYELOID LEUKEMIA AND THEIR CORRELATION WITH SURVIVAL
M. Schmitt, J. Greiner, L. Li, K. Giannopoulos, K. Boesch, K. Döhner, R.F. Schlenk, J.R. Pollack, H. Döhner, L. Bullinger (University of Ulm, Ulm, Germany)
 
0110 PROGNOSIS OF ACUTE MYELOID LEUKEMIA PATIENTS <60 YEARS WITH TRISOMY 8 AS A SOLE ABERRATION: POOLED DATA ANALYSIS OF THE GERMAN ACUTE MYELOID LEUKEMIA INTERGROUP
M. Schaich, R.F. Schlenk, H. Döhner, A. Ganser, G. Heil, T. Illmer, R. Krahl, J. Krauter, D. Niederwieser, C. Sauerland, S. Soucek, T. Büchner, G. Ehninger (Universitätsklinikum C.G.Carus, Dresden, Germany)
 
0111 PROGNOSTIC IMPACT OF THE NPM1/FLT3 ITD MUTATION STATUS IN ELDERLY PATIENTS (>60 YEARS OF AGE) WITH NORMAL KARYOTYPE AML: RESULTS OF AMLSG TREATMENT TRIAL AML HD98B
K. Döhner, A. Corbacioglu, B. Krebs, S. Hein, L. Bullinger, S. Fröhling, H. Döhner, R.F. Schlenk (University of Ulm, Ulm, Germany)
 
0112 PROGNOSTIC DETERMINANTS IN ADULT AML PATIENTS WITH INTERMEDIATE RISK KARYOTYPE
F. Buccisano, L. Maurillo, G. Del Poeta, M.I. Del Principe, P. Panetta, D. Fraboni, M. Mazzone, L. Giannì, S. Campagna, D. Renzi, C. Sarlo, L. Franceschini, V. Gattei, F. Lo Coco, S. Amadori, A. Venditti (Tor Vergata University Hospital, Rome, Italy)
 
0113 ROLE OF DNA METHYLTRASFERASES (DNMTS) AND POLYCOMB GROUP OF PROTEINS (PCG) IN LEUKEMIA
L. Di Croce (Centre for Genomic Regulation, Barcelona, Spain)
 
0114 TRISOMY 8 AS SOLE ANOMALY OR WITH OTHER CLONAL ABERRATIONS IN ACUTE MYELOID LEUKEMIA: IMPACT ON CLINICAL PRESENTATION AND TREATMENT OUTCOME
X. Thomas, N. Jaff, Y. Chelghoum, M. Elhamri, I. Tigaud, M. Michallet (Edouard Herriot Hospital, Lyon, France)
 
0115 ANALYSIS OF 1458 ACUTE MYELOID LEUKEMIA FROM THE ALERT PROJECT (ACUTE LEUKEMIA CLINICAL REGISTER) IN THE CZECH REPUBLIC IN 1996-2006
I.K. Indrak, D.M. Doubek, V.J. Voglová, K.V. Koza, K.T. Kozák, S.T. Szotkowski, M.J. Mayer, Z.P. Z? ák, C.P. Cetkovsk´y, M.K. Michalová, J.M. Jaros? ová, S.K. Steinerová, M.J. Muz? ík, D.L. Dus? ek, M.J. Maaloufová (University Hospital, Olomouc, Czech Republic)
 
0116 CLORETAZINE(R)‚ (VNP40101M) HAS SIGNIFICANT ACTIVITY AS INDUCTION THERAPY FOR ELDERLY PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR ADVANCED MYELODYSPLASTIC SYNDROME (MDS)
J. Giles, D. Rizzieri, J. Karp, K.D. Khan, G. Mufti, G. Verhoef, P.W. Wijermans, A. Advani, V. Karsten, R. Geller, S. O'Brien, N. Vey (MD Anderson Cancer Center, Houston, USA)
 
0117 DOSING OF TROXATYL (TROXACITABINE, SGX-145) BASED ON RENAL FUNCTION
M.J. Kelner, J. Giles, J. Feldman, J. Roboz, J. DeAngelo, A. Lokker, K. Burley (University of California, San Diego, San Diego, USA)
 
0118 CYTOGENETIC RESPONSES IN OLDER PATIENTS WITH AML AND COMPLEX KARYOTYPE TREATED WITH LOW- DOSE 5-AZA-2'- DEOXYCYTIDINE (DECITABINE)
B. Rüter, S. Knipp, U. Germing, M. Lübbert (University of Freiburg, Freiburg, Germany)
 
0119 SINGLE POINT MUTATIONS IN THE JUXTAMEMBRANE DOMAIN OF FLT3 ARE RARELY FOUND IN AML PATIENTS AND DEFINE THE THIRD CLASS OF ACTIVATING MUTATIONS
C. Reindl, K. Bagrintseva, S. Vempati, S. Schnittger, J.W. Ellwart, K. Wenig, K.P. Hopfner, W. Hiddemann, K. Spiekermann (GSF-Hämatologikum, Munich, Germany)
 
0120 ORIGINAL DATA BASED META-ANALYSIS ON PATIENTS >60 YEARS OF AGE WITH CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA - RESULTS OF THE GERMAN AMLINTERGROUP
R.F. Schlenk, R. Krahl, C. Sauerland, T. Büchner, S. Soucek, M. Schaich, G. Ehninger, A. Ganser, K. Döhner, H. Döhner, D. Niederwieser (University of Ulm, Ulm, Germany)
 
0121 THE KINETICS OF REDUCTION OF MINIMAL RESIDUAL DISEASE IMPACTS ON DURATION OF RESPONSE AND SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA
F. Buccisano, L. Maurillo, G. Del Poeta, M.I. Del Principe, P. Panetta, M. Mazzone, D. Fraboni, G. De Angelis, M. Postorino, M. Ales, R. Cerretti, M. Rizzo, V. Gattei, F. Lo Coco, S. Amadori, A. Venditti (Tor Vergata University Hospital, Rome, Italy)
 
0122 CLOFARABINE AS FIRST-LINE TREATMENT OF ELDERLY (>= 65 YEARS OF AGE) AML PATIENTS WITH AN UNFAVOURABLE CYTOGENETIC PROFILE WHO ARE UNSUITABLE FOR STANDARD TREATMENT
A.K. Burnett, M. Baccarani, P. Johnson, J. Yin, N. Russell (University of Wales College of Medicine, Cardiff, United Kingdom)
 
0123 ABCB1 (PGP) AND ABCG2 (BCRP) PROTEINS ARE INDEPENDENT PROGNOSTIC FACTORS FOR COMPLETE REMISSION AND RELAPSE RISK, RESPECTIVELY, IN NORMAL KARYOTYPE ADULT DE NOVO ACUTE MYELOID LEUKEMIA
M. Tiribelli, D. Damiani, E. Calistri, A. Geromin, A. Chiarvesio, A. Michelutti, M. Cavallin, R. Fanin (Division of Hematology and BMT, Udine, Italy)
 

ACUTE MYELOID LEUKEMIA II

 
0124 IMMUNOPHENOTYPIC PATTERN OF HIGH RISK KARYOTYPE ACUTE MYELOID LEUKEMIA IS CHARACTERIZED BY EXPRESSION OF CD34 AND LACK OF MPO
M. Sierra, M.B. Vidriales, J.J. Pérez, N.C. Gutierrez, I. Recio, R. Cuello, F. Ramos, A. Martin-Sancho, J.A. Rodriguez, J.L. Garcia, J.M. Hernandez, J.F. San Miguel (Hospital Clinico U. Salamanca, Salamanca, Spain)
 
0125 ABNORMALITIES IN P53 AND P14ARF IN DE NOVO AML PREDICTS A VERY SHORT OVERALL SURVIVAL AND IN VITRO DRUG-RESISTANCE.
H. Nahi, M. Merup, S. Lehmann, S. Bengtzen, M. Jansson, L. Möllgård, C. Paul (Karolinska University Hospital, Stockholm, Sweden)
 
0126 LEUKEMIA IN UKRAINIAN CLEAN-UP WORKERS OF THE CHERNOBYL ACCIDENT: EPIDEMIOLOGIC AND HEMATOLOGIC ASPECTS
D. Bazyka, A. Romanenko, D. Bazyka, V. Bebeshko (Research Center for Radiation Medicine, Kyiv, Ukraine)
 
0127 QUANTITATIVE ASSESMENT OF AML/ETO FUSION TRANSCRIPT AS USEFUL TOOL FOR MINIMAL RESIDUAL DISEASE DETECTION AND OUTCOME PREDICTION IN T(8;21) AMLS
E. Messa, D. Cilloni, E. Ottaviani, M. Fava, E. Gottardi, F. Messa, F. Arruga, I. Defilippi, P. Nicoli, S. Carturan, A. Guerrasio, G. Martinelli, G. Saglio (University of Turin, Orbassano, Italy)
 
0128 PROGNOSTIC SIGNIFICANCE OF BAALC EXPRESSION IN ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE: FROM MICROARRAY TO RQPCR ASSAY
N. Maroc, O. Biglia, V. Forestier, A. Martinec, N. Borie, N. Carbuccia, N. Vey, D. Birnbaum, M.J. Mozziconacci, F. Hermitte (Ipsogen, Marseille, France)
 
0129 A MULTICENTER PROSPECTIVE RANDOMIZED STUDY OF LENOGRASTIM (RHG-CSF) IN CONSOLIDATION CHEMOTHERAPY FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (JALSG GML200-S STUDY)
S. Ohtake, F. Yagasaki, S. Miyawaki, M. Matsuda, H. Taguchi, T. Matsushima, K. Toba, M. Yoshida, T. Naoe, R. Ueda, R. Ohno (Kanazawa University, Kanazawa, Japan)
 
0130 INTERPRETATION OF INTERLEUKIN-2 RECEPTOR ALPHA POSITIVE CELLS DURING INDUCTION CHEMOTHERAPY FOR ADULT ACUTE MYELOGENOUS LEUKEMIA PATIENTS
H.J. Kim, H.Y. Jeong, Y. Choi, S.Y. Kim, K.S. Eom, S. Lee, C.K. Min, S.G. Cho, J.W. Lee, W.S. Min, C.C. Kim (CHSCTC,Catholic Univ. of Korea, Seoul, South-Korea)
 
0131 INHIBITION OF FLT3-ACTIVATING MUTATIONS MAY NOT PREVENT CONSTITUTIVE ACTIVATION OF ERK/AKT/STAT PATHWAYS IN SOME AML SAMPLES: A POSSIBLE CAUSE FOR THE LIMITED EFFECTIVENESS OF THERAPY WITH SMALL-MOLECULE INHIBITORS
C.H. Lopez-Pedrera, E. Siendones, N. Barbarroja, P Buendia, A Torres, F Velasco (Hospital "Reina Sofia", Cordoba, Spain)
 
0132 THE PRESENCE OF FLT3 MUTATIONS DOES NOT IMPAIR STEM CELL MOBILIZATION AND FEASIBILITY OF AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA
F. Ferrara, S. Palmieri, F. Pollio, C. Lo Pardo, D. Graziano, C. Falco, M.R. D'Amico, M. Celentano, L. Vicari, B. Izzo, F. Pane (Cardarelli Hospital, Napoli, Italy)
 
0133 MYELOABLATIVE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL INFUSION MAY OVERCOME THE ADVERSE PROGNOSTIC IMPACT OF FLT3 MUTATIONS IN ACUTE MYELOID LEUKAEMIA
F. Ferrara, S. Palmieri, F. Leoni, S. Ciolli, M.R. D'Amico, F. Pollio, M. Celentano, B. Izzo, F. Pane (Cardarelli Hospital, Napoli, Italy)
 
0134 PEDIATRIC RELAPSED ACUTE MYELOID LEUKEMIA (AML) IN THE NETHERLANDS FROM 1980 UNTIL 2000
B.F. Goemans, K. Corbijn, R.Y.J. Tamminga, K. Hahlen, G.J.L. Kaspers (VU university Medical Center, Amsterdam, The Netherlands)
 
0135 PROTEIN KINASE CK2ALPHA AS AN INDEPENDENT PROGNOSTIC MARKER AND A NOVEL THERAPEUTIC TARGET IN ACUTE MYELOID LEUKEMIA
Y.H. Min, J.I. Eom, J.Y. Cho, J.W. Cheong, J.S. Kim, Y.R. Kim, I.H. Park, J.K. Lee, W.I. Yang (Yonsei Universtiy College of Medicine, Seoul, South-Korea)
 
0136 INTERLEUKIN-2 CAN BE SAFELY ADMINISTERED TO AML PATIENTS IN 1ST CR AFTER AN AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
S.M. Trisolini, S. Capria, L. Cardarelli, V. Gianfelici, G.A. Natale, M. Ribersani, F. Mandelli, R. Foà, G. Meloni (La Sapienza University, Roma, Italy)
 
0137 STEM CELL DETECTION IN AML PATIENTS UNDER REMISSION CONDITIONS: A NEW ERA IN MINIMAL RESIDUAL DISEASE DETECTION?
A. van Rhenen, N. Feller, A. Kelder, B. Moshaver, A.H.W. Westra, S. Zweegman, G.J. Ossenkoppele, G.J. Schuurhuis (VU University Medical Center, Amsterdam, The Netherlands)
 
0138 ANALYSIS OF X-CHROMOSOME INACTIVATION PATTERNS IN IRANIAN PATIENTS WITH AML DURING REMISSION
Y. Mortazavi, S. Kaviani, K. Alimoghaddam, A.A. Pourfathollah (Zanjan Medical School, Zanjan, Iran)
 
0139 PROGNOSTIC ROLE OF EOSINOPHILIA AND CYTOGENETICS ON TREATMENT RESPONSE AND SURVIVAL IN AML-M4. THE GIMEMA EXPERIENCE
A. Pulsoni, S. Iacobelli, A. Matturro, P. Fazi, M. Vignetti, F. Ferrara, F. Di Raimondo, M. Sborgia, A. Venditti, A. Camera, G. Specchia, G. Leone, F. Mandelli, R. Foa', L. Pagano (La Sapienza University, Rome, Italy)
 
0140 POLYMORPHISMS IN THE RAD51 AND XRCC-3 GENES INCREASE THE RISK OF DEVELOPING ACUTE MYELOID LEUKAEMIA
E. Fabiani, F. Guidi, F. D'Alo', M. Giachelia, D. Gumiero, G. Leone, M.T. Voso (Universita' Cattolica S. Cuore, Rome, Italy)
 
0141 THE ANTI-PROLIFERATIVE AND APOPTOSIS-INDUCING EFFECTS OF THE PROTEASOME INHIBITORS BORTEZOMIB AND PR-171 IN ACUTE MYELOGENOUS LEUKAEMIA
C. Stapnes, A. Døskekand, K.J. Hatfield, E. Ersvær, B.T. Gjertsen, Ø. Bruserud (Institute of Medicine, Bergen, Norway)
 
0142 SINGLE CELL ANALYSIS OF PHOSPHOINOSITIDE 3-KINASE/AKT AND ERK ACTIVATION IN ACUTE MYELOID LEUKEMIA BY FLOW CYTOMETRY
V. Bardet, J. Tamburini, N. Ifrah, F. Dreyfus, P. Mayeux, C. Lacombe, D. Bouscary (Institut Cochin, Paris, France)
 

CHRONIC MYELOID LEUKEMIA I

 
0143 ABERRANT EXPRESSION OF CELLULAR RETINOL-BINDING PROTEIN-1 (CRBP-1) IN MEGAKARYOCYTES AND MARROW STROMA CELLS OF CHRONIC MYELOPROLIFERATIVE AND MYELODYSPLASTIC/MYELOPROLIFERATIVE DISORDERS
A.H. Schmitt-Graeff, M. Lübbert, C. F. Waller, M.L. Bochaton-Piallat, G. Gabbiani (Institute of Pathology Universityhospit, Freiburg, Germany)
 
0144 CHRONIC MYELOID LEUKEMIA (CML) CELLS EXPRESS TUMOR ASSOCIATED ANTIGENS ELICITING SPECIFIC CD8+ T CELL RESPONSES AND ARE LACKING COSTIMULATORY MOLECULES
L. Li, A. Schmitt, J. Chen, K. Giannopoulos, C. Brunner, K. Döhner, H. Döhner, J. Greiner (University of Ulm, Ulm, Germany)
 
0145 MOLECULAR RESPONSE AT 6 MONTHS IS A GOOD EARLY PREDICTOR OF DURATION OF TREATMENT RESPONSE IN IMATINIBTREATED CHRONIC PHASE CHRONIC MYELOID LEUKAEMIA (CML)
M. Ross, S. Branford, J. Reynolds, R. Koelmeyer, T.P. Hughes (IMVS, Adelaide, Australia)
 
0146 BCR-ABL PEPTIDE VACCINATION INDUCES ADDITIONAL MOLECULAR IMPROVEMENT IN IMATINIB-RESPONSIVE CHRONIC MYELOID LEUKAEMIA (CML)
L. Wang, J. Rojas, K. Knight, C. Lucas, R. Clark (Royal Liverpool University Hospital, Liverpool, United Kingdom)
 
0147 P210 BCR-ABL TYROSINE KINASE INTERACTS WITH HISTONE DEACETYLASE 1 IN CHRONIC MYELOID LEUKAEMIA HAEMATOPOIETIC PROGENITORS: CONSEQUENCES ON HISTONE H4 ACETYLATION AND CHROMATIN STRUCTURE
G. Brusa, M. Mancini, E. Zuffa, P. Corrado, S. Luatti, E. Barbieri, M.A. Santucci (Università di Bologna, Bologna, Italy)
 
0148 BCR/ABL ONCOGENIC KINASE DISRUPTS MISMATCH RECOGNITION AND REPAIR COMPLEX TO INDUCE GENOMIC INSTABILITY
T. Stoklosa, A. Slupianek, G. Basak, T. Skorski (The Medical University of Warsaw, Warsaw, Poland)
 
0149 COMPARATIVE PROTEOMIC ANALYSIS OF CHRONIC MYELOGENOUS LEUKEMIA CELLS : INSIDE THE MECHANISM OF IMATINIB RESISTANCE
V. Santini, G. Ferrari, A. Gozzini, R. Pastorelli (University of Florence, Firenze, Italy)
 
0150 DASATINIB (D) IN PATIENTS (PTS) WITH CHRONIC MYELOGENOUS LEUKEMIA (CML) IN MYELOID BLAST CRISIS (MBC) THAT IS IMATINIB-RESISTANT (IM-R) OR IM-INTOLERANT (IM-I): RESULTS OF THE CA180006 'START-B' STUDY
M. Baccarani, J. Cortes, D.W. Kim, T. Facon, J.F. Apperley, P. Rousselot, E. Bleickardt, R. Zink, M. Muller, C. Sawyers (University of Bologna, Bologna, Italy)
 
0151 A PHASE II STUDY OF NILOTINIB (AMN107), A NOVEL INHIBITOR OF BCR-ABL, ADMINISTERED TO IMATINIB-RESISTANT OR INTOLERANT PATIENTS WITH PH+ CHRONIC MYELOGENOUS LEUKEMIA (CML) IN BLAST CRISIS (BC) OR RELAPSED/ REFRACTORY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
O.G. Ottmann, R. Larson, P. Le Coutre, M. Baccarani, T. Rafferty, L. Alland, H. Kantarjian, T. Hughes, F. Giles (University of Frankfurt, Frankfurt, Germany)
 
0152 A STUDY OF BCR-ABL MUTATIONS IN PATIENTS WITH IMATINIBRESISTANT CML AND PH+ALL PATIENTS ENROLLED IN A NILOTINIB (AMN107) PHASE I STUDY
J. Giles, K. Bhalla, H. Kantarjian, A. Hochhaus, M. Muller, D. Jones, K. Dawson, K. Rose, L. Alland, M. Dugan, S. Lilleburg, O. Ottman (MD Anderson Cancer Center, Houston, USA
 
0153 ROLE OF ENDOTHELIAL PROGENITOR CELLS IN MYELOPROLIFERATIVE DISEASES
C. Zwicky, E. Oppliger Leibundgut, M.P. Horn, C. Brunold, B. Pfanner-Meyer, D. Marti, H. Hirsiger, A. Tobler, G. Baerlocher (University Berne, Berne, Switzerland)
 
0154 COMPLIANCE AND PERSISTENCY WITH IMATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS
W. Feng, J. Henk, K. Thomas, J. Baladi, A. Hatfield, A. Goldberg, J. Cortes (Novartis Pharmaceuticals Corporation, Florhem Park, USA)
 
0155 COMPARISON BETWEEN CONVENTIONAL AND MOLECULARLY DEFINED THERAPEUTICS IN A CONDITIONAL BCR-ABL CELL CULTURE MODEL
A. Chaturvedi, K. Battmer, M. Scherr, M. Eder, A. Ganser (Hannover Medical school, Hannover, Germany)
 
0156 A PHASE II STUDY OF NILOTINIB (AMN107) A NOVEL INHIBITOR OF BCR-ABL, ADMINISTERED TO IMATINIB-RESISTANT OR INTOLERANT PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA (CML) IN ACCELERATED PHASE (AP)
H. Kantarjian, O. Ottmann, N. Gattermann, R. Larson, T. Rafferty, L. Alland, F. Giles, S.G. O'Brien, P. Le Coutre (The University of Texas MD Anderson Canc, Houston, USA)
 
0157 IMATINIB 800 MG IN INTERMEDIATE SOKAL RISK PATIENTS IN EARLY CHRONIC PHASE: RESULTS OF A PHASE II TRIAL OF THE GIMEMA CML WORKING PARTY
G. Rosti, F. Castagnetti, M. Amabile, N. Testoni, G. Marzocchi, M. Breccia, F. Palandri, C. Bigazzi, A. Poerio, F. Stagno, F. Iuliano, E. Abruzzese, F. Pane, G. Saglio, G. Martinelli, M. Baccarani (University of Bologna, Bologna, Italy)
 
0158 PHILADELPHIA-POSITIVE HEMATOPOIETIC PROGENITORS ARE NOT DETECTABLE IN CML PATIENTS TREATED WITH IMATINIB ACHIEVING A MAJOR MOLECULAR RESPONSE
A. Ibatici, M. Podesta, G. Fugazza, N. Sessarego, A. Garuti, S. Pozzi, M. Corselli, F. Bertolotti, M. Sessarego, F. Patrone, F. Frassoni (Ospedale San Martino, Genova, Italy)
 
0159 DASATINIB (D) IN PATIENTS (PTS) WITH ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA (AP-CML) RESISTANT OR INTOLERANT TO IMATINIB: RESULTS OF THE CA180005 'START-A' STUDY
F. Guilhot, J.F. Apperley, A. Hochhaus, R. Silver, S. Amadori, A. Gratwohl, S. Cheng, M. Iyer, J. Radich, M. Talpaz (CHU La Miletrie, Poitiers, France)
 
0160 INVOLVEMENT OF RAS, JAK2 AND GM-CSF IN THE PATHOGENESIS OF PROLIFERATIVE VARIANT OF CHRONIC MYELOMONOCYTIC LEUKEMIA
F. Onida, F. Servida, C. Ricci, E. Fermo, M.C. Pasquini, A. Vismara, A. Cortelezzi, S. Soligo, G. Lambertenghi-Deliliers (Matarelli Foundation for Blood Diseases, Milano, Italy)
CHRONIC MYELOID LEUKEMIA II

 
0161 TRANSCRIPTIONAL PROFILING OF PRIMARY IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA
O. Frank, B. Brors, A. Fabarius, L. Li, C. Zheng, M.C. Müller, R. Hehlmann, A. Hochhaus, W. Seifarth (Universität Heidelberg, Mannheim, Germany)
 
0162 MONITORING SERUM LEVELS OF IMATINIB AND HAEMATOLOGICAL TOXICITY IN CML PATIENTS
M. Perez-Abad, J. Perez-Oteyza, M.I. Arranz Peña, J. Lopez Jimenez, J. Garcia Laraña, E. Ripoll Sevillano (Ramon y Cajal Hospital, Madrid, Spain)
 
0163 IMATINIB PRECEDING ALLOGENEIC STEM CELL TRANSPLANTATION IN CHRONIC MYELOID LEUKAEMIA
J.B. Perz, D. O`Shea, J. Sanz, A. Chaidos, J. Kaeda, D. Marin, E. Eduardo, J.F. Apperley (University Heidelberg, Heidelberg, Germany)
 
0164 EARLY OR LATE COMPLETE MOLECULAR REMISSIONS IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS TREATED WITH IMATINIB RELY ON THE SPEED TO ACHIEVE A COMPLETE CYTOGENETIC REMISSION (CCR) STATUS AND ON EARLY QUANTITATIVE BCR-ABL LEVELS
F.E. Nicolini, E. Bachy, S. Corm, C. Plesa, Q.H. Lê, S. Hayette, C. Preudhomme, M. Michallet (Edouard Herriot Hospital, Lyon, France)
 
0165 THE IMPACT OF NON-COMPLIANCE WITH IMATINIB THERAPY ON HEALTH CARE COSTS IN CHRONIC MYELOID LEUKEMIA PATIENTS
W. Feng, J. Henk, K. Thomas, J. Baladi, A. Hatfield, A. Goldberg, J. Cortes (Novartis Pharmaceuticals Corporation, Florhem Park, USA)
 
0166 MOLECULAR RESPONSE TO IMATINIB IN EARLY CHRONIC PHASE VERSUS LATE CHRONIC PHASE CML PATIENTS IN COMPLETE CYTOGENETIC RESPONSE: A COMPARISON AT 24 MONTHS OF 2 CLINICAL TRIALS OF THE GIMEMA-CML WP
A. Poerio, G. Rosti, M. Amabile, I. Iacobucci, S. Soverini, S. Colarossi, A. Gnani, E. Ottaviani, C. Terragna, T. Grafone, S. Luatti, F. Castagnetti, F. Pane, G. Saglio, M. Baccarani, G. Martinelli (Inst.of Hematology "Seràgnoli", Bologna, Italy)
 
0167 HOMOHARRINGTONINE IS ASSOCIATED WITH A HIGH PROPORTION OF HEMATOLOGIC RESPONSE IN CML PATIENTS WITH HEMATOLOGIC FAILURE TO IMATINIB
P.R. Rousselot, A.S. De Sarrazin, J.M.C. Cayuela, O.M. Maarek, M.P.G. Gaub, F.M. Maloisel (Hôpital Mignot, Le Chesnay, France)
 
0168 ACETYLOME AND PHOSPHOPROTEOME MODIFICATIONS OF IMATINIB SENSITIVE AND RESISTANT CML CELLS AFTER SHORT CHAIN FATTY ACID HISTONE DEACETYLASE INHIBITOR TREATMENT
V. Santini, R. Pastorelli, G. Ferrari, A. Gozzini, D. Tombaccini (University of Florence, Firenze, Italy)
 
0169 IMATINIB THERAPY FOR CHRONIC MYELOID LEUKEMIA PATIENTS WHO RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A MOLECULAR ANALYSIS
F.P. Palandri, M. Amabile, G. Bandini, F. Benedetti, M. Usala, E. Angelucci, M. Tiribelli, R. Fanin, G. Rosti, G. Martinelli, M. Baccarani (University of Bologna, Bologna, Italy)
 
0170 INFLUENCE OF CYP3A4 ACTIVITY ON IMATINIB RESPONSE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
H. Gréen, K. Skoglund, F. Rommel, L. Bertilsson, K. Lotfi (Linköping University, Linköping, Sweden)
 
0171 IMATINIB 400 MG IN LOW SOKAL RISK CML PATIENTS: EARLY RESULTS OF AN OBSERVATIONAL, MULTICENTRIC TRIAL OF THE GIMEMA CML WP
G. Rosti, F. Castagnetti, I. Iacobucci, N. Testoni, M. Breccia, F. Palandri, G. Specchia, B. Martino, S. Luatti, A. Capucci, A. Poerio, R. Bassan, F. Pane, G. Saglio, G. Martinelli, M. Baccarani (University of Bologna, Bologna, Italy)
 
0172 IMATINB AND AGING: PRELIMINARY RESULTS OF A SUBANALYSIS WITHIN 3 TRIALS OF THE GIMEMA CML WP
F. Castagnetti, G. Rosti, I. Iacobucci, N. Testoni, M. Amabile, E. Usala, D. Russo, E. Orlandi, S. Soverini, E. Montefusco, G. Rege Cambrin, S. Rupoli, G. Martinelli, F. Pane, G. Saglio, M. Baccarani (University of Bologna, Bologna, Italy)
 
0173 BCR-ABL REDUCES CCN3 EXPRESSION THEREBY EVADING NEGATIVE GROWTH REGULATION
L. McCallum, S. Price, W. Lu, N. Planque, B. Perbal, A.D. Whetton, A.E. Irvine (Queen's University Belfast, Belfast, United Kingdom)
 
0174 THE PERSISTENCE OF P190 BCR-ABL TRANSCRIPTS IS ASSOCIATED WITH LOWER PROBABILITY OF MOLECULAR RESPONSE TO IMATINIB IN EARLY AND LATE CHRONIC PHASE CML PATIENTS
A. Ibatici, A. Garuti, S. Pozzi, G. Cirmena, F. Bertolotti, M. Miglino, N. Sessarego, R. Varaldo, N. Colombo, M. Podesta, M. Gobbi, M. Sessarego, F. Patrone, F. Frassoni (Ospedale San Martino, Genova, Italy)
 
0175 IMPACT OF BCR/ABL GENE EXPRESSION ON THE PROLIFERATIVE RATE OF DIFFERENT SUBPOPULATIONS OF HEMATOPOIETIC CELLS IN CHRONIC MYELOID LEUKEMIA
D. Primo, J. Flores, S. Quijano, M.L. Sanchez, M.E. Sarasquete, J. Del Pino-Montes, P.I. Gaarder, M. Gonzalez, A. Orfao (Centro de Investigación del Cáncer, Salamanca, Spain)
 
0176 SURVIVIN AND CIAP-1 GENE EXPRESSION IS LINKED TO CHRONIC MYELOID LEUKEMIA PROGRESSION AND POOR RESPONSE TO IMATINIB
F.A. Castro, J.F. Jacysyn, A.G. Ulbrich, P.R. Tobo, L.R. Lopes, D.L.C. Alves, M.A. Zanichelli, M.D. Colassantti, D. Camanho, C.A. Moreira-Filho, N. Hamerschlak, G.P. Amarante-Mendes (FCFRP-USP, Ribeirão Preto, Brazil)
 
0177 ABL KINASE DOMAIN MUTATIONS ARE IMPORTANT MECHANISMS OF RESISTANCE IN ASIAN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKAEMIA
T.H. Chuah, Y.T. Goh, L.H. Lee, M. Koh, L.P. Koh, Y. Loh, R. Yiu, L.C. Lim, G.F. How, O. Otheris, J. Tan (Singapore General Hospital, Singapore, Singapore)
 
0178 INCREASED ANGIOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: CLINICAL AND MORPHOLOGICAL ANALYSIS
A. Zhelyazkova, L. Gercheva, P. Kolova, A. Tonchev, L. Ivanova (Varna University of Medicine, Varna, Bulgaria)
 

NON-HODGKIN’S LYMPHOMA - CLINICAL I

 
0179 A PHASE II, MULTICENTER, SINGLE-AGENT STUDY OF BENDAMUSTINE HCL IN PATIENTS WITH RITUXIMAB-REFRACTORY INDOLENT B-CELL NON-HODGKIN'S LYMPHOMA
A. Forero-Torres, J. Foran, P. Cohen, B.D. Cheson, K.S. Robinson, L. Fayad, A.S. La Casce, A. Bessudo, E.S. Camacho, M.E. Williams, R.H. van der Jagt, J.W. Oliver, J.W. Friedberg (University of Alabama at Birmingham, Birmingham, Al, USA)
 
0180 CLINICAL FEATURES AND PROGNOSTIC ASSESSMENT OF NODAL MARGINAL ZONE B-CELL LYMPHOMA, A RARE DISEASE WITH FOLLICULAR-LIKE BEHAVIOUR
L. Arcaini, M. Paulli, E. Boveri, A. Rossi, M. Spina, F. Passamonti, S. Burcheri, M. Montanari, A. Gallamini, L. Uziel, C. Crugnola, C. Pascutto, E. Morra, M. Lazzarino (IRCCS Policlinico San Matteo, Pavia, Italy)
 
0181 PRELIMINARY EVALUATION OF EFFICACY AND TOXICITY OF TWO DOSES SCHEDULES OF BORTEZOMIB PLUS R-CHOP REGIMEN IN FRONT-LINE B LYMPHOMA PATIENTS
F. Remy, V. Ribrag, N. Mounier, C. Haioun, G. Salles, J.B. Golfier, C. Ferme, J. Briere, M. Ertault, P. Brice, C. Gisselbrecht (Hôpital Saint-Louis, Paris, France)
 
0182 CLINICAL FEATURES AND TREATMENT OUTCOMES OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
W.S. Kim, B.B. Park, B.Y. Ryoo, Y.H. Ko, C.W. Suh, J.R. Huh, Y.H. Park, S.S. Lee, S.M. Bang, H.C. Kwon, H.J. Kim, K.W. Park, J.H. Kim, J.H. Kang, K.H. Kim, K.C. Park, E.K. Cho (Samsung Medical Center, Seoul, South-Korea)
 
0183 AUTOIMMUNE DISEASES IN PATIENTS WITH MALT-LYMPHOMA: CHARACTERISTICS AND CLINICAL COURSE
S. Wöhrer, M. Troch, B. Streubl, J. Zwerina, C.C. Zielinski, A. Chott, M. Raderer (Medical University of Vienna, Vienna, Austria)
 
0184 RITUXIMAB-M/VACOP-B COMBINED WITH RADIOTHERAPY IN PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA (PMLBCL): A PROSPECTIVE ITALIAN INTERGROUP PHASE II STUDY
M. Martelli, V. Stefoni, P. Cabras, S. Cortellazzo, E. Brusamolino, A. Levis, E. Gallo, A. De Vivo, F. Natalino, E. Finolezzi, A. Di Rocco, R. Foà, P.L. Zinzani (University "La Sapienza", Roma, Italy)
 
0185 ASSOCIATION OF REDUCED RELATIVE DOSE INTENSITY AND SURVIVAL IN LYMPHOMA PATIENTS RECEIVING CHOP-21 CHEMOTHERAPY
R. Pettengell, M. Schwenkglenks, D. Bron, P. Johnson, A. Van Hoof, B. Hancock, R. De Bock, A. Pagliuca, Z. Berneman, R. Thomas, A. Ferrant, M. Joyner, M. Dauwe, G. Verhoef, P. Hoskin, A. Bosly (St. George's Hospital, London, United Kingdom)
 
0186 THE EMERGING ROLE OF FDG PET/CT IN THE PRIMARY STAGING OF LYMPHOMA
J. Trotman, M. Fulham, M. Gibson, A. Mohamed, I. Cunningham, G. Young (Concord Hospital, Sydney, Australia)
 
0187 BORTEZOMIB PLUS RITUXIMAB IN PATIENTS WITH INDOLENT NONHODGKINS LYMPHOMA (NHL): A PHASE 2 STUDY
A. Goy, S. De Vos, S. Dakhil, P. McLaughlin, M. Saleh, R. Belt, C. Flowers, M. Knapp, L. Hart, D. Patel-Donnelly, M. Glenn, S. Gregory, C. Holladay, A. Boral, T. Zhang (Hackensack University Medical Center, Hackensack, USA)
 
0188 CONSOLIDATION OF CHEMOTHERAPY RESPONSE IN MANTLE CELL LYMPHOMA (MCL) PATIENTS WITH 90Y-IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY (RIT)
W.J. Jurczak, M.S. Szostek, A.G. Giza, D.K. Krochmalczyk, J.W. Wegrzyn, A.H. Hubalewska-Dydejczyk, A.S. Sowa-Staszczak, A.H. Hellmann, W.K. Knopinska-Posluszny, B.Z. Zdziarska, S.K. Krycz- Krzemien, L.P. Poplawska, A.S. Skotnicki (CMUJ, Kopernika, Poland)
 
0189 MT103 (ANTI-CD19 X ANTI-CD3 BITE) INDUCES B CELL DEPLETION, CLEARANCE OF BONE MARROW INFILTRATION AND CLINICAL RESPONSES IN HEAVILY PRETREATED NHL PATIENTS: FIRST DATA FROM DOSE-ESCALATION STUDY MT103-104
R. Bargou, P. Kufer, P. Kirchinger, R. Noppeney, M. Schuler, A. Viardot, K. Weigang-Köhler, F. Zettl, M. Libicher, G. Riethmüller, R. Lutterbüse, M. Klinger, C. Reinhardt, P. Bäuerle (Medizinische Klinik II, Würzburg, Germany)
 
0190 PKC-BETA II EXPRESSION HAS PROGNOSTIC IMPACT IN NODAL DIFFUSE LARGE B-CELL LYMPHOMA
R.S. Schaffel (Federal University of Rio de Janeiro, Rio De Janeiro, Brazil)
 
0191 CIGARETTE SMOKING AND ALCOHOL CONSUMPTION AS DETERMINANTS OF SURVIVAL IN NON-HODGKIN'S LYMPHOMA: A POPULATION-BASED STUDY
T. Battaglioli, G. Gorini, A. Seniori Costantini, P. Crosigani, L. Miligi, O. Nanni, S. Stagnaro, R. Tumino, P. Vineis (IRCCS Maggiore Hospital, Milan, Italy)
 
0192 IBRITUMOMAB TIUXETAN COMBINED WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH CHEMOREFRACTORY AGGRESSIVE NON-HODGKIN'S LYMPHOMA
A. Shimoni, T. Zwass, Y. Oksman, I. Hardan, N. Shem-Tov, R. Yerushalmi, A. Avigdor, I. Ben-Bassat, A. Nagler (Chaim Sheba Medical Center, Tel-hashomer, Israel)
 
0193 CENTRAL NERVOUS SYSTEM INVOLVEMENT IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA. INCIDENCE AND CLINICAL CHARACTERISTICS
M. Arnan, E. Gonzalez-Barca, E. Domingo-Domenech, A. Oliveira, E. Pina, J. Petit, J. Sarra, M. Encuentra, A. Fernandez de Sevilla (Institut Catala d'Oncologia, L'hospitalet De Llobregat, Spain)
 
0194 CLINICAL FEATURES OF THE WESTERN AND ASIAN FORMS OF INTRAVASCULAR LYMPHOMA (IVL) VARIES ACCORDING TO THE PRESENCE OF HEMOPHAGOCYTIC SYNDROME (HPS) AND NOT TO THE GEOGRAPHICAL AREA
A.J.M. Ferreri, G.P. Dognini, E. Campo, E. Zucca, M. Martelli, A. De Renzo, C. Doglioni, M. Ferracci, C. Montalban, A. Tedeschi, A. Pavlovsky, A. Morgan, L. Uziel, S. Ascani, U. Gianelli, C. Patriarca, F. Facchetti, L. Mazzucchelli, F. Cavalli, M. Ponzoni (San Raffaele Scientific Institute, Milan, Italy)
 
0195 A PHASE II STUDY OF CYCLOPHOSPHAMIDE, VINCRISTINE, NON-PEGYLATED LIPOSOMAL DOXORUBICIN, AND PREDNISONE PLUS RITUXIMAB (RCOMP) IN ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
M. Federico, M.D. Caballero, E. Thiel, S. Bologna, M.J.S. Dyer, S. Luminari (Università di Modena e Reggio Emilia, Modena, Italy)
 
0196 INDUCTION WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB FOLLOWED BY RITUXIMAB MAINTENANCE IS A HIGHLY EFFECTIVE FRONT-LINE TREATMENT FOR PATIENTS WITH FOLLICULAR LYMPHOMA: RESULTS FROM A COOPERATIVE SPANISH TRIAL
J.F. Tomas, C. Montalban, J. Martinez, A. Fernandez de Sevilla, J. Paz, M. Canales, J. Diaz-Mediavilla, P. Sanchez-Godoy, M.D. Caballero, J. Peñalver, E. Prieto, A. Salar, C. Burgaleta, J.A. Queizan, A. Sanchez Salinas, J. de la Serna (MD Anderson International España, Madrid, Spain)
 
0197 INTENSIVE CHEMOTHERAPY (HIGH-DOSE CHOP/ESHAP REGIMEN) FOLLOWED BY AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) IN PREVIOUSLY UNTREATED PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (PTCL)
S. Mercadal Vilchez, A. López-Guillermo, M. Camós, E. Montserrat, B. Xicoy, J.M. Ribera, L. Lourdes, C. Pedro, C. Estany, J. Briones, R. Martino (H.Clinic, Barcelona, Spain)
 
0198 THE ADDITION OF RITUXIMAB TO CHEMOTHERAPY MAY CHANGE PROGNOSTIC FACTORS, INCLUDING TUMOR BCL-2 EXPRESSION, IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
L. Arenillas, A. Lopez-Guillermo, L. Colomo, A. Martinez-Pozo, F. Bosch, S. Mercadal, J. Carreras, O. Balaguer, N. Villamor, O. Salamero, J. Esteve, E. Campo, E. Montserrat (Hospital Clinic, Barcelona, Spain)
 

NON-HODGKIN’S LYMPHOMA - CLINICAL II

 
0199 CLINICAL OUTCOME OF LOW GRADE NON HODGKIN'S LYMPHOMA PATIENTS WITH BONE MARROW INVOLVEMENT DETECTED BY FLOW CYTOMETRY ALONE
M. Lishner, N. Gronich, J. Radnay, H. Shapiro, Y. Manor, M. Lahav (Meir Medical Center, Kfar Saba, Israel)
 
0200 CHOP (DOXORUBICIN) CHEMOTHERAPY IS SUPERIOR TO CNOP (MITOXANTRONE) IN THE TREATMENT OF PATIENTS WITH AGGRESSIVE NON-HODGKIN LYMPHOMA (REVIEW)
M. Björkholm, T. Andersson, A. Ahlbom, E. Ösby (Karolinska University Hospital, Stockholm, Sweden)
 
0201 EARLY-MID TREATMENT C-REACTIVE PROTEIN (CRP) LEVELS PREDICT TIME TO DISEASE PROGRESSION OR RELAPSE AS WELL AS OVERALL SURVIVAL IN AGGRESSIVE NON-HODGKIN'S LYMPHOMA
Y. Herishanu, C. Perry, U. Metzer, L. Gibpstein, S. Trestman, O. Goor, A. Polliack, E. Napartek (Tel-Aviv Sourasky Medical Center, Tel-aviv, Israel)
 
0202 BEAC OR BEAM CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN NON-HODGKIN'S LYMPHOMA PATIENTS: COMPARATIVE ANALYSIS ON EFFICACY AND TOXICITY
C. Suh, J.E. Koo, S. Kim, Y.H. Cho, Y.K. Kang, J. Huh (Asan Medical Center, Seoul, South-Korea)
 
0203 RAPID INFUSION OF RITUXIMAB WITH OR WITHOUT STEROID CONTAINING CHEMOTHERAPY. ONE YEAR EXPERIENCE IN A SINGLE CENTRE
A. Salar, D. Casao, M. Cervera, C. Pedro, E. Gimeno, E. Abella, A. Alvarez- Larrán, M. Calafell, C. Besses (Hospital del Mar, Barcelona, Spain)
 
0204 RITUXIMAB PLUS CLADRIBINE OR CLADRIBINE AND CYCLOPHOSPHAMIDE IN HEAVILY PRETREATED PATIENTS WITH INDOLENT LYMPHOPROLIFERATIVE DISORDERS
T.R. Robak, P. Smolewski, A. Szmigielska-Kaplon, B. Cebula, J.Z. Blonski, K. Chojnowski (Medical University of Lodz, Lodz, Poland)
 
0205 A RETROSPECTIVE STUDY TO ASSESS RELATIVE DOSE INTENSITIES IN PATIENTS WITH LYMPHOMA IN CENTRAL EUROPEAN COUNTRIES
M. Trnen ´y, S. Fekete, J. Walewski, M. Ladicka, G. Kreuzbauer, T. Skacel (Charles University General Hospital, Prague, Czech Republic)
 
0206 COMPARISON BETWEEN 2-DEOXY-2-[18F]FLUORO-D-GLUCOSE POSITRON EMISSION (FDG-PET) AND COMPUTER TOMOGRAPHY (CT) FOR STAGING OF PATIENTS WITH HODGKIN'S LYMPHOMA (HL)
L. Rigacci, F. Merli, A. Castagnoli, A. Versari, L. Nassi, T. Chisesi, A. Gallamini, A. Biggi, U. Vitolo, R. Sancetta, P. Pregno, F. Salvi, A.M. Scattolin, A. Levis, A. Bosi (Azienda Ospedaliera Universitaria, Florence, Italy)
 
0207 MARKED ACTIVITY OF BORTEZOMIB, RITUXIMAB, AND DEXAMETHASON (BORID) IN HEAVILY PRETREATED PATIENTS WITH MANTLE CELL LYMP
J. Drach, H. Kaufmann, O. Pichelmayer, V. Sagaster, S. Seidl, A. Chott, C. Zielinski, M. Raderer (Medical University Vienna, Vienna, Austria)
 
0208 CLINICAL AND CYTOGENETIC CHARACTERISTICS OF HIGH-GRADE NONHODGKIN LYMPHOMA (HGNHL) WITH A COMBINATION OF T(14;18) TRANSLOCATION AND C-MYC REARRANGEMENT: A VERY AGGRESSIVE ENTITY WITH A DISMAL PROGNOSIS.
C.T. Touzeau, N.M. Morineau, H.A.L. Avet-Loiseau, R.G. Garand, P.T. Talmand, A.M. Moreau, T.G. Gastinne, N.M. Milpied, P.M. Moreau, J.L.H. Harousseau, S.L.G. Le Gouill (CHU Nantes, Nantes, France)
 
0209 TRANSPLANT REGIMENS FOR HIGH-RISK MANTLE CELL LYMPHOMA: THE EFFECT OF INCORPORATING IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY ON RELAPSE RATE
A.K. Krishnan, A.R. Raubitschek, S.F. Forman, H.F. Fung, A.M. Molina, D.Y. Yamauchi, P.F. Falk, R.S. Spielberger, L.P. Popplewell, R.R. Rodriguez, P.P. Parker, W.C. Chow, R.N. Nakamura, AN Nademanee (City of Hope National Cancer Center, Duarte, USA)
 
0210 GASTRECTOMY PLUS CHEMOTHERAPY VS. CHEMOTHERAPY ALONE IN GASTRIC DIFFUSE LARGE B-CELL LYMPHOMA OF EARLY STAGE
D. Mihou, P. Konstantinidou, D. Markala, Fr. Patakiouta, N. Constantinou ("Theagenion" Cancer Center, Thessaloniki, Greece)
 
0211 PREDICTORS OF SURVIVAL IN ELDERLY PATIENTS WITH AGGRESSIVE LYMPHOMA. A LONG-TERM FOLLOW-UP OF A RANDOMISED TRIAL
S.Y. Kristinsson, E. Ösby, H. Hagberg, S. Kvaloy, L. Teerenhovi, H. Anderson, H. Holte, E. Cavallin-Stahl, J. Myhre, A. Ost, H. Pertovaara, B. Nilsson, M. Björkholm (Karolinska University Hospital, Solna, Sweden)
 
0212 UPDATE REPORT ON 78 PATIENTS WITH POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS FOLLOWED BY A SINGLE CENTER
E. Ravelli, V. Mancini, G. Muti, P. Oreste, M. Nichelatti, E. Morra (Niguarda Ca' Granda Hospital, Milan, Italy)
 
0213 RISK OF SECOND CANCER IN NON-GASTRIC MARGINAL ZONE B-CELL LYMPHOMA OF MALT: A POPULATION-BASED STUDY FROM NORTHERN ITALY
S. Burcheri, L. Arcaini, A. Rossi, C. Pascutto, F. Passamonti, M. Paulli, E. Orlandi, F. Montanari, M. Buelli, P. Viero, M. Lucioni, E. Rumi, A. Algarotti, S. Cortelazzo, M. Lazzarino (IRCCS Policlinico San Matteo, Pavia, Italy)
 
0214 ACHIEVEMENT OF MOLECULAR REMISSION AFTER FIRST LINE TREATMENT PROLONGS SURVIVAL IN FOLLICULAR LYMPHOMA PATIENTS
V.P. Prochazka, Z. Kubová, T. Papajík, R. Plach?, Z. Pikalová, L. Raida, L. Kucerová, K. Indrák, RoÏmanová (Teaching Hospital, Olomouc, Czech Republic)
 
0215 CLINICO-BIOLOGICAL CHARACTERISTICS OF PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA AND HEPATITIS C VIRUS INFECTION
H. Ionita, M. Iordache, I. Ionita, D. Calamar-Popovici, M. Ionita, D. Oros, C. Ionita (UMF Victor Babes, Timisoara, Romania)
 
0216 RITUXIMAB IN INDUCTION TREATMENT AND IN HIGH DOSE CHEMOTHERAPY (HDC) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION AS FIRST LINE THERAPY IN STAGE III-IV DIFFUSE LARGE B-CELL LYMPHOMA AT POOR PROGNOSIS
U. Vitolo, G. Rossi, M.G. Cabras, A.M. Liberati, A. Chiappella, E. Pavone, E. Angelucci, B. Botto, M. Ceccarelli, S. Cortelazzo, R. Freilone, E. Pogliani, D. Rota Scalabrini, F. Salvi, A. Tucci, E. Gallo (ASO S. Giovanni Battista, Torino, Italy)
 
0217 EFFECTS OF PRE-TRANSPLANTATION TREATMENT WITH RITUXIMAB ON OUTCOMES OF AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR DIFFUSE LARGE B-CELL LYMPHOMA
P.O. Obrtlikova, B. Vackova, R. Pytlik, H. Krejcova, P. Klener, M. Trneny (Charles University General Hospital, Prague 2, Czech Republic)
 
0218 COMPARATIVE ANALYSIS OF TREATMENT OUTCOMES WITH CHOP REGIMEN, ETOPOSIDE PLUS CORTICOSTEROID AND PREDNISOLONE IN ADULT PATIENTS WITH HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: BASED ON UNDERLYING DISEASES
H.-J. Shin, J.S. Chung, Y.J. Choi, G.J. Cho, H.-J. Kim, Y.-K. Kim, D.-H. Yang, S.K. Sohn, J.G. Kim, Y.D. Joo, W.S. Lee (Pusan National University Hospital, Busan, South-Korea)
 

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES I

 
0219 PP2500 MRNA, A SPLICE VARIANT OF THE MULTIPLE ANKIRIN REPEAT SINGLE KH DOMAIN (MASK), IS HIGHLY EXPRESSED IN PLASMA CELLS OF MULTIPLE MYELOMA
A.S.S.D. Duarte, M.M. Ortega, F.F. Costa, C.S.P Lima, S.T.O. Saad (Hemocentro- State University of Campinas, Campinas, Brazil)
 
0220 A PHASE II STUDY OF THALIDOMIDE, DEXAMETHASONE AND PEGYLATED LYPOSOMAL DOXORUBICIN (THADD) FOR UNTREATED PATIENTS WITH MULTIPLE MYELOMA AGED OVER 65 YEARS
M.O. Offidani, L.C. Corvatta, M.M. Marconi, C.P. Polloni, M.N.P. Piersantelli, G.V. Visani, F.A. Alesiani, M.B. Brunori, C.M. Bigazzi, M.C. Catarini, M.B. Burattini, R.C. Centurioni, L.M. Morbidoni, A.P. Poloni, P.L. Leoni (Clinica di Ematologia, Ancona, Italy)
 
0221 MONOKINE-INDUCED BY INTERFERON-GAMMA (MIG) SERUM LEVELS ARE A MARKER OF DISEASE LOAD AND CORRELATE WITH PROGNOSIS IN MULTIPLE MYELOMA
M. Schreder, G. Koch, D. Heintel, K. Strasser-Weippl, U. Jäger, H. Ludwig, N. Zojer (Wilhelminenspital, Vienna, Austria)
 
0222 VAD-DOXIL VS.VAD-DOXIL PLUS THALIDOMIDE AS INITIAL TREATMENT IN MYELOMA PATIENTS: INTERIM ANALYSIS OF A MULTICENTER RANDOMIZED TRIAL OF THE GREEK MYELOMA STUDY GROUP
K. Zervas, D. Mihou, I. Katodritou, A. Pouli, C.H. Mitsouli, A. Anagnostopoulos, S. Delibasi, M.C. Kyrtsonis, N. Anagnostopoulos, E. Terpos, P. Zikos, A. Maniatis, M.A. Dimopoulos ("Theagenion" Cancer Center, Thessaloniki, Greece)
 
0223 THE COMBINATION OF BORTEZOMIB, MELPHALAN, DEXAMETHASONE AND INTERMITTENT THALIDOMIDE (VMDT) IS AN EFFECTIVE REGIMEN FOR RELAPSED/REFRACTORY MYELOMA AND REDUCES SERUM LEVELS OF RANKL, MIP-1 ALPHA AND ANGIOGENIC CYTOKINES
E. Terpos, A. Anagnostopoulos, E. Kastritis, D. Christoulas, A. Zomas, C. Poziopoulos, N. Anagnostopoulos, K. Tsionos, M.A. Dimopoulos (251 General Airforce Hospital, Athens, Greece)
 
0224 BORTEZOMIB DEMONSTRATES SUPERIOR SURVIVAL COMPARED WITH HIGH DOSE DEXAMETHASONE AND HIGHER RESPONSE RATES AFTER EXTENDED FOLLOW-UP IN THE APEX TRIAL IN RELAPSED MULTIPLE MYELOMA
P. Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J.L. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J. san Miguel, J. Blade, M. Boccadoro, J. Cavenagh, K. Anderson (Dana-Farber Cancer Institute, Boston, USA)
 
0225 SIMPLE, BUT SIGNIFICANT FACTORS FOR SURVIVAL AFTER AUTOLOGOUS TRANSPLANTATION IN 181 MULTIPLE MYELOMA PATIENTS: A SINGLE CENTRE EXPERIENCE
M. Krejci, R. Hajek, A. Svobodnik, A. Krivanova, Z. Adam, L. Pour, J. Vorlicek (Faculty Hospital Brno, Brno, Czech Republic)
 
0226 IDENTIFICATION OF NOVEL GENE EXPRESSION SUBGROUPS IN MULTIPLE MYELOMA USING UNSUPERVISED CLUSTER ANALYSIS
E. Kamst, P. Sonneveld (ErasmusMC, Rotterdam, The Netherlands)
 
0227 EFFICACY OF SINGLE-AGENT BORTEZOMIB VERSUS THALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW
- Prince, M. Adena, D. Kingsford Smith, J. Hertel (Peter MacCallum Cancer Centre, Melbourne, Australia)
 
0228 BORTEZOMIB IN RELAPSED MULTIPLE MYELOMA: RESPONSE RATES AND DURATION OF RESPONSE ARE INDEPENDENT OF CHROMOSOME 13Q
J. Drach, E. Küenburg, V. Sagaster, N. Zojer, J. Ackermann, H. Kaufmann, V. Odelga, C. Zielinski, R. Wieser, H. Ludwig (Medical University Vienna, Vienna, Austria)
 
0229 INTEGRATIVE GENOMIC ANALYSIS OF MULTIPLE MYELOMA PATIENTS WITH 13Q DELETION SUGGESTS A ROLE OF CHROMOSOMAL ABERRATIONS IN THE TRANSCRIPTIONAL FINGERPRINT
L. Agnelli, A. Callegaro, G. Poretti, S. Fabris, D. Verdelli, I. Kwee, L. Baldini, F. Morabito, A. Zanella, G. Lambertenghi-Deliliers, F. Bertoni, S. Bicciato, L. Lombardi, A. Neri (Fondazione IRCCS Ospedale Policlinico, Milano, Italy)
 
0230 EFFICACY AND SAFETY OF MELPHALAN/ARSENIC TRIOXIDE/ASCORBIC ACID COMBINATION THERAPY (MAC) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE, MULTICENTER, PHASE II, SINGLE-ARM STUDY
R. Berenson, R. Boccia, D. Siegel, M. Bozdech, A. Bessudo, E. Stadtmauer, J.T. Pomeroy, R. Steis, M. Flam, J. Lutzky, S. Jilani, J. Volk, T. Lindgren, R. Moss, R. Patel, H.S. Yeh (Inst. for Myeloma & Bone Cancer Research, West Hollywood, California, United States of America)
 
0231 INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) IS OVEREXPRESSED IN MULTIPLE MYELOMA PLASMA CELLS (PC) AND REGULATES THE EXPRESSION OF THE IGF-1 RECEPTOR
M.R. Renzulli, C. Terragna, N. Testoni, C. Nicci, C. Taccioli, T. Grafone, P. Tosi, E. Zamagni, P. Tacchetti, G. Perrone, M. Toccafondi, G. Martinelli, M. Baccarani, M. Cavo (Institute of Hematology, Bologna, Italy)
 
0232 AUTOIMMUNITY IS ASSOCIATED WITH BETTER SURVIVAL IN MULTIPLE MYELOMA
O. Landgren, R.M. Pfeiffer, D. Baris, G. Gridley, L. Mellemkjaer, K. Hemminki, L.R. Goldin, N.E. Caporaso (National Cancer Institute, NIH, Bethesda, Maryland, USA)
 
0233 BORTEZOMIB AND HIGH DOSE MELPHALAN: A NEW CONDITIONING REGIMEN BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA
D. Roussel, C. Danho, A. Huynh, L. Ysebaert, C. Recher, F. Huguet, C. Nouvel, G. Laurent, M. Attal (CHU Purpan, Toulouse, France)
 
0234 ENOXAPARIN OR ASPIRIN FOR THE PREVENTION OF RECURRENT THROMBOEMBOLISM IN NEWLY DIAGNOSED MYELOMA PATIENTS TREATED WITH MELPHALAN AND PREDNISONE PLUS THALIDOMIDE OR LENALIDOMIDE
A. Palumbo, C. Rus, F. Cavallo, A. Bertola, M.T. Petrucci, A.M. Liberati, P. Musto, F. Pisani, S. Morandi, J. Zeldis, F. Rodeghiero, M. Boccadoro (Divisione di Ematologia Univ. Torino, Torino, Italy)
 
0235 INTERMEDIATE-DOSE MELPHALAN (100MG/M2), THALIDOMIDE, DEXAMETHASONE (MVTD) AND STEM CELL SUPPORT IN PATIENTS WITH REFRACTORY OR RELAPSED MYELOMA
P. Musto, I. Avonto, P.R. Scalzulli, B. Bruno, A. Falcone, M.T. Ambrosini, S. Bringhen, F. Gay, C. Rus, F. Cavallo, P. Falco, M. Massaia, M. Boccadoro, A. Palumbo (Italian Myeloma Network, Gimema, Italy)
 
0236 THALIDOMIDE-DEXAMETHASONE VS THALIDOMIDEDEXAMETHASONE AND PEGYLATED LIPOSOMAL DOXORUBICIN: A CASE-MATCHED STUDY IN PATIENTS WITH ADVANCED MULTIPLE MYELOMA
M.O. Massimo, S.B. Bringhen, L.C. Corvatta, M.M. Marconi, P.F. Falco, I.A. Avonto, G.V. Visani, F.A. Alesiani, M.B. Brunori, M. Ruggieri, M.C. Catarini, M.N.P. Piersantelli, C.P. Polloni, P.L. Leoni, A.P. Palumbo (Clinica di Ematologia, Ancona, Italy)
 
0237 DYSFUNCTION OF TOLL-LIKE RECEPTORS: A POSSIBLE IMPLICATION IN THE PATHOGENESIS OF IMMUNODEFICIENCY IN MULTIPLE MYELOMA
E. Andreakos, M.A. Dimopoulos, K. Tsionos, C. Xirakia, A. Anagnostopoulos, E. Katodritou, K. Zervas, P. Sideras, E. Terpos (Academy of Athens, Athens, Greece)
 
0238 CLINICOPATHOLOGICAL CORRELATES OF PLASMA CELLS CD56 (NCAM) EXPRESSION IN MULTIPLE MYELOMA
M. Kraj, U. Sokolowska, J. Kopec- Szlezak, R. Poglod, B. Kruk, J. Wozniak, K. Owczarska (Institute of Haematology and Blood Trans, Warsaw, Poland)
 

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES I

 
0239 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN MULTIPLE MYELOMA, SOLITARY PLASMOCYTOMA AND MONOCLONAL GAMMAPATHY OF UNKNOWN SIGNIFICANCE
Z.A. Adam (University Hospital, Brno, Czech Republic)
 
0240 TREATMENT WITH BENDAMUSTINE, THALIDOMIDE AND PREDNISOLONE (BPT) IN ADVANCED MYELOMA PATIENTS: RESULTS OF A PHASE I CLINICAL TRIAL
W. Pönisch, M. Rozanski, F.A. Hoffmann, T.H. Boldt, A. Schwarzer, U. Ruffert, J. Uhlig, R. Rohrberg, U. Kreibich, D. Niederwieser (University of Leipzig, Leipzig, Germany)
 
0241 CANTHARIDIN, A DERIVATIVE OFBLISTER BEATLES INDUCES APOPTOSIS IN MULTIPLE MYELOMA CELLS VIA INHIBITION OF IL-6-INDUCIBLE STAT3 PATHWAY: NEW AGENT FOR SIGNAL TRANSDUCTION THERAPY OF MULTIPLE MYELOMA
M.S. SAGAWA, T.N. Nakazato, Y.I. Ikeda, M.K. Kizaki (KEIO University School of Medicine, Tokyo, Japan)
 
0242 CITRULLINE CONCENTRATION AFTER HIGH-DOSE MELPHALAN IN AUTOLOGOUS HSCT RECIPIENTS
N.M.A Blijlevens, J.P. Donnelly, A.V.M.B. Schattenberg, T.J.M. de Witte (UMC St. Radboud, Nijmegen, The Netherlands)
 
0243 PLASMA CELL PROPIDIUM IODIDE (PC-PI/CD138) AND ANNEXIN V (PCAI/ CD138) INDICES IN MULTIPLE MYELOMA AND MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE - EARLY PREDICTORS OF TRANSFORMATION?
J.M. Minarik, V.S. Scudla, M.O. Ordeltova, J.B. Bacovsky, M.Z. Zemanova, T.P. Pika (3rd Department of Internal Medicine, Olomouc, Czech Republic)
 
0244 EPIDEMIOLOGY OF ANEMIA IN 720 PATIENTS WITH MULTIPLE MYELOMA: RESULTS FROM EUROPEAN ANAEMIA SURVEY (ECAS)
H. Ludwig, P. Gascón, S. Van Belle, - For ECAS Investigators (Wilhelminenspital, Vienna, Austria)
 
0245 A PHASE I/II STUDY OF ARSENIC TRIOXIDE, BORTEZOMIB, AND ASCORBIC ACID IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
R. Berenson, J. Matous, D. Ferretti, R.A. Swift, R. Mapes, B. Morrison, H.S. Yeh (Inst. for Myeloma & Bone Cancer Research, West Hollywood, California, USA)
 
0246 PREVALENCE OF RAS GENE MUTATIONS IN THE CONTEXT OF A MOLECULAR CLASSIFICATION OF MULTIPLE MYELOMA
D. Intini, L. Agnelli, S. Fabris, G. Ciceri, L. Nobili, L. Baldini, F. Morabito, S. Bicciato, L. Lombardi, A. Zanella, G. Lambertenghi-Deliliers, A. Neri (Fondazione IRCCS Ospedale Policlinico, Milano, Italy)
 
0247 PERSONAL HISTORY OF REPEATED PNEUMONIA IS ASSOCIATED WITH INCREASED RISK OF MULTIPLE MYELOMA
O. Landgren, J. Rapkin, L. Mellemkjaer, G. Gridley, L.R. Goldin, E.A. Engels (National Cancer Institute, NIH, Bethesda, Maryland, USA)
 
0248 MINIMAL RESIDUAL DISEASE CAN BE DETECTED IN ALMOST ALL MULTIPLE MYELOMA PATIENTS IN REMISSION USING A COMBINED APPROACH OF FIVE-COLOUR FLOW CYTOMETRY AND INTERPHASE FISH ON SUBSEQUENTLY SORTED PLASMA CELLS
S. Franke, B. Maes, M. Berten, G. Bries, V. Madoe, K. Magerman, A. Mewis, P. Declercq, R. Cartuyvels, V. Peeters, K. Hensen, J.L. Rummens (Virga Jesse Hospital, Hasselt, Belgium)
 
0249 BORTEZOMIB TRANSIENTLY INHIBITS OSTEOCLAST ACTIVITY IN CELL CULTURE CONDITIONS MIMICKING IN VIVO INTERMITTENT TREATMENT
P. Boissy, T. Plesner, J.M. Delaisse (Vejle Hospital, Vejle, Denmark)
 
0250 COMBINATION THERAPY EFFECTS OF LENALIDOMIDE IN FGFR3 MULTIPLE MYELOMA CELL LINES
A. Gandhi, J. Kang, L. Capone, P. Schafer, W. Sherman, D. Stirling (Celgene Corporation, Summit, USA)
 
0251 A NOVEL IN VIVO ANIMAL MODEL FOR HUMAN MULTIPLE MYELOMA BASED ON BIOLUMINESCENCE IMAGING OF TUMOR CELL GROWTH
H. Rozemuller, I. Koggel, R. Spaapen, A. Hagenbeek, A.C.M. Martens (University Medical Center, Utrecht, The Netherlands)
 
0252 RELATIVE QUANTIFICATION OF TUMOR ASSOCIATED ANTIGENS MAGE-A1 AND MAGE-A3 IN MULTIPLE MYELOMA
J.V. Vigasova, J. Kadlecova, R. Spesna, R. Gaiyllova, M. Penka, J. Michalek, R. Hajek (Faculty Hospital Brno, Brno- Bohunice, Czech Republic)
 
0253 POST RELAPSE AND OVERALL SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA THAT PROGRESSED AFTER DECEMBER 1998
I.H. Hardan, A.S. Shimoni, A.K. Kneller, A.A. Avigdor, M.B. Bercowicz, I.D. Davidiwits, N.S. Shem-Tov, M.L. Leiba, R.Y. Yerushalmi, I.B. Ben-Bassat, A.N. Nagler (Sheba Medical enter, Tel-hashomer, Israel)
 
0254 OPG/ RANKL SYSTEM IN MULTIPLE MYELOMA
V.S Goranova-Marinova, S.E. Goranov, P.I. Pavlov, A.D. Bojadzhieva (University Hospital "Sv.Georgi", Plovdiv, Bulgaria)
 
0255 SAFETY AND EFFICACY OF BORTEZOMIB FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DAILY ONCOLOGY PRACTICE
H. Freimann, A. Calderoni, P. Cornu, R.A. Olie (KSSW Kantonales Spital Sursee- Wolhusen, Sursee, Switzerland)
 
0256 MULTIPLE MYELOMA (MM) IN BRAZIL: CLINICAL AND DEMOGRAPHIC FEATURES AND THE UTILITY OF ISS IN 1,017 PATIENTS, MOSTLY WITH ADVANCED DISEASE
V. Hungria, A. Maiolino, G. Martinez, A.C.C. Choair, E.O.M. Coelho, L. Rocha, R.F.M. Nunes, L.M.R. Silla, L. Oliveira, R.M.D. Faria, R. Pasquini, S.M.M. Magalhães, C.A. Souza, J.V. Pinto Neto, L. Barreto (Santa Casa de Sao Paulo, Sao Paulo, Brazil)
 
0257 EVALUATION OF 4 STAGING SYSTEMS IN 470 MYELOMA PATIENTS: VALIDATION OF THE SUPERIOR PROGNOSTIC SIGNIFICANCE OF THE INTERNATIONAL STAGING SYSTEM
D. Mihou, I. Katodritou, D. Markala, K. Zervas ("Theagenion" Cancer Center, Thessaloniki, Greece)
 
0258 OSTEONECROSIS OF THE JAW IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH BISPHOSPHONATES: A SINGLE CENTER EXPERIENCE
E. Verrou, A. Banti, E. Terpos, D. Mihou, Z. Teleioudis, D. Krikelis, K. Vahtsevanos, K. Zervas ("Theagenion" Cancer Center, Thessaloniki, Greece)
 

CLL AND RELATED DISORDERS - CLINICAL / EXPERIMENTAL I

 
0259 DETECTION OF RISK-IDENTIFYING MARKERS AND ADDITIONAL ABERRATIONS BY MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION (MLPA) IN CHRONIC LYMPHATIC LEUKEMIA
A. Buijs, P.J. Krijtenburg, E. Meijer (UMC Utrecht, Utrecht, The Netherlands)
 
0260 QUANTITATIVE GENE EXPRESSION ANALYSIS OF SURROGATE MARKERS FOR GENETIC RISK GROUPS AND SURVIVAL IN CLL
D. Kienle, A. Benner, A. Kröber, D. Winkler, P. Lichter, R. Dalla-Favera, H. Döhner, S. Stilgenbauer (University of Ulm, Ulm, Germany)
 
0261 DISTINCT EXPRESSION LEVELS OF NOXA IN PERIPHERAL VERSUS LYMPH NODE CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE LINKED WITH SURVIVAL CAPACITY
E. Eldering, L.A. Smit, D.Y.H. Hallaert, R. Spijker, B. de Goeij, M.H.J. van Oers, C.J. van Noesel (Academical Medical Center, Amsterdam, The Netherlands)
 
0262 SIGNIFICANT CORRELATION BETWEEN OBJECTIVE RESPONSES AND EXPOSURE TO HUMAX-CD20 IN CHRONIC LYMPHOCYTIC LEUKEMIA
B. Coiffier, H. Tilly, L.M. Pedersen, T. Plesner, H. Frederiksen, M.H.J. van Oers, J. Woolridge, J. Kloczko, J. Holowiecki, A. Hellmann, J. Walewski, M.F. Flensburg, J. Petersen, T. Robak (Centre Hospitalier Lyon Sud, Pierre-benite Cedex, France)
 
0263 CD40 LIGATION SENSITIZES P53 DYSFUNCTIONAL CLL CELLS TO CHEMOTHERAPY INDUCED APOPTOSIS VIA THE P73 PATHWAY
A.P. Kater, F. Dicker, C.E. Prada, J.E. Castro, T.J. Kipps (Academic Medical Center, Amsterdam, The Netherlands)
 
0264 RHAMM/CD168 IS A NOVEL LEUKEMIA ASSOCIATED ANTIGEN WITH PROGNOSTIC VALUE FOR PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
K.G. Giannopoulos, A. Kröber, A. Dmoszynska, J. Rolinski, H. Döhner, S. Stilgenbauer, M. Schmitt (Medical University of Lublin, Lublin, Poland)
 
0265 PARTHENOLIDE INDUCES REACTIVE OXYGEN SPECIES AND SELECTIVE APOPTOSIS OF B-CHRONIC LYMPHOCYTIC LEUKAEMIA CELLS VIA A P53 INDEPENDENT PATHWAY
J. Steele, G. Prentice, A.V. Hoffbrand, B. Mehta, K. Ganeshaguru, R.G. Wickremasinghe (Royal Free and UCL Medical School, London, United Kingdom)
 
0266 SMALL MOLECULE PAN-BCL2 FAMILY INHIBITOR OBATOCLAX (GX15- 070): FINAL RESULTS OF A SINGLE AGENT PHASE I TRIAL IN PATIENTS WITH REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
S. O'Brien, D. Claxton, M. Crump, S. Faderl, T. Kipps, M. Keating, B. Cheson (MD Anderson Cancer Center, Houston, USA)
 
0267 COMPARISON OF EX VIVO DRUG SENSITIVITY BY TRAC ASSAY AND PATIENT RESPONSE IN THE UK LRF CLL4 TRIAL
A.G. Bosanquet, S.L. Raper, J. Durant, S.M. Scadding, S.M. Richards, D. Catovsky (Bath Cancer Research, Bath, United Kingdom)
 
0268 INTRACELLULAR CYTOKINE EXPRESSION BY B AND T CELLS DIFFERS IN ZAP-70 POSITIVE AND ZAP-70 NEGATIVE B-CLL PATIENTS
M. Podhorecka, A. Bojarska-Junak, J. Rolinski, A. Dmoszynska (Medical University of Lublin, Lublin, Poland)
 
0269 ACCUMULATION OF T-CELLS WITH EXTREMELY SHORT TELOMERES IN T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL)
A. Röth, J. Dürig, H. Himmelreich, R. Siebert, S. Bug, U. Dührsen, P. Lansdorp, G. Baerlocher (University Hospital Essen, Essen, Germany)
 
0270 INTRACLONAL DIVERSIFICATION OF IMMUNOGLOBULIN LIGHT CHAIN VARIABLE REGION GENES IN CHRONIC LYMPHOCYTIC LEUKEMIA
E. Kostareli, K. Stamatopoulos, A. Daglis, C. Belessi, A. Hadzidimitriou, N. Stavroyianni, T. Smilevska, V. Tachynopoulou, M. Gounari, F. Marantidou, N. Laoutaris, A. Anagnostopoulos, A. Fassas, A. Kouvatsi (Aristotle University, Biology School, Thessaloniki, Greece)
 
0271 QUANTITATION OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA USING LNA-MODIFIED FLUORESCENTLY LABELED PROBES AND REAL-TIME PCR TECHNOLOGY
P.S. Pekova, S.L. Saudkova, S.L. Smolej, K.T. Kozak (Hospital Na Homolce, Prague 5, Czech Republic)
 
0272 ADOPTIVE IMMUNOTHERAPY OF B-CELL MALIGNANCIES WITH A TRIFUNCTIONAL, BISPECIFIC ANTIBODY (ANTI-CD3 X ANTICD20) AND ALLOGENEIC DONOR LYMPHOCYTE TRANSFUSION
R. Buhmann, M. Stanglmaier, B. Simoes, T. Yang, P. Ruf, H. Lindhofer, H.J. Kolb (GSF, Munich, Germany)
 
0273 TELOMERE LENGTH IS A PROGNOSTIC FACTOR STRONGER THAN VH-MUTATIONAL STATUS IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL)
I. Ricca, R. Francese, A. Rocci, D. Drandi, C. Lobetti Bodoni, M. Compagno, E. Genuardi, M. Rosace, M. Astolfi, P. Omedè, A. Gallamini, C. Marinone, L. Bergui, M. Boccadoro, C. Tarella, M. Ladetto (University of Turin, Torino, Italy)
 
0274 HIGHLY SENSITIVE DETECTION OF MINIMAL RESIDUAL DISEASE IN B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA BY INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION ON FLOW SORTED CELLS
K. Hensen, S. Franke, H. Jongen, V. Peeters, P. Declercq, K. Magerman, A. Mewis, R. Cartuyvels, J.L. Rummens, B. Maes (Virga Jesse Hospital, Hasselt, Belgium)
 
0275 MRD KINETIC AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (SCT) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CAN PREDICT INDIVIDUAL TIME TO RELAPSE AND IS ASSOCIATED WITH CLINICAL OUTCOME AND IGVH MUTATIONAL STATUS
M. Ritgen, S. Boettcher, S. Stilgenbauer, H. Dohner, M. Bruggemann, C. Pott, T. Raff, N. Schmitz, R. Busch, M. Hallek, M. Kneba, P. Dreger (Universitätsklinikum Schleswig-Holstein, Kiel, Germany)
 
0276 MDR-1, BUT NOT MDR-3 GENE EXPRESSION, IS ASSOCIATED WITH UNMUTATED IGVH GENES AND POOR PROGNOSIS CHROMOSOMAL ABERRATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA
H.D. Alexander, C. Matthews, M.A. Catherwood, A. Larkin, M. Clynes, T.C.M. Morris (Belfast City Hospital Trust, Belfast, Northern Ireland)
 
0277 ANTILEUKEMIC ACTIVITY OF LENALIDOMIDE (L) {REVLIMID} IN PATIENTS (PTS) WITH RELAPSED (REL) OR REFRACTORY (REF) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
A. Chanan-Khan, K. Miller, L. Musial, S. Padmanabhan, D. Lawrence, Z. Bernstein, K. Takeshita, D. Spaner, C. Byrne, C. Crystal, M. Czuczman (Roswell Park Cancer Institute, Buffalo, USA)
 
0278 ZAP-70 EXPRESSION IN B-CLL IS ASSOCIATED WITH INCREASED RISK OF AUTOIMMUNE CYTOPENIAS
R. Zanotti, A. Ambrosetti, A. Andreoli, M. Chilosi, M. Lestani, A. Remo, F. Frattini, A. Andreini, G. Pizzolo (Section of Hematology, Verona, Italy)
 
0279 IN-VITRO TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS WITH FLUDARABINE, ETOPOSIDE AND ALEMTUZUMAB (CAMPATH-1H) LEADS TO SPECIFIC MECHANISMS AND RATES OF CELL DEATH IN DIFFERENT GENETIC SUBGROUPS
D. Winkler, C. Schneider, D. Nitsch, A. Habermann, H. Döhner, St. Stilgenbauer (Uniklinik Ulm, Ulm, Germany)
 
0280 ANALYSIS OF EXPRESSED AND NON-EXPRESSED IMMUNOGLOBULIN LAMBDA LOCUS REARRANGEMENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
E. Tsakou, A. Daglis, C. Belessi, K. Stamatopoulos, A. Hadzidimitriou, N. Stavroyianni, C. Vadikolia, E. Kalagiakou, G. Kokkini, G. Paterakis, C. Georgopoulos, R. Saloum, A. Anagnostopoulos, A. Fassas, N. Laoutaris (Nikea General Hospital, Pira